Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
Conditions: Acute Coronary Syndrome
Sponsor: Brigham and Women's Hospital

Replication of the ISAR-REACT 5 Trial in Healthcare Data Claims
NCT 01944800
August 3, 2021

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
1. RCT Details
This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely
as possible given the remaining limitations inherent in the healthcare databases.
1.1 Title
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes (ISAR-REACT 5 trial) 
1.2 Intended aim(s) 
To compare ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and prasugrel (60-mg loading dose, 10 mg daily 
thereafter) for the prevention of cardiovascular events in patients admitted to the hospital with an acute coronary 
syndrome, with or without ST-segment elevation, who were scheduled to undergo coronary angiography. 
1.3 Primary endpoint for replication and RCT finding 
The primary outcome was composite of death, myocardial infarction, or stroke at 1 year after randomization 
1.4 Required power for primary endpoint and noninferiority margin (if applicable) 
Assuming an incidence of 10.0% in ticagrelor users and 12.9% in prasugrel users, 1,895 patients would be required for each 
group to achieve 80% power to detect a relative risk reduction of 22.5% in the rate of the primary outcome in the ticagrelor 
group as compared with the prasugrel group, using a two-sided alpha of 0.05. 
1.5 Primary trial estimate targeted for replication 
HR = 1.36 (95% CI 1.09–1.70) comparing ticagrelor to prasugrel (Schupke et al., 2019) 
2. Person responsible for implementation of replication in Aetion
Dureshahwar Jawaid, MPH implemented the study design in the Aetion Evidence Platform. She is not responsible for the validity
of the design and analytic choices. All implementation steps are recorded, and the implementation history is archived in the
platform.
3. Data Source(s)
Optum, MarketScan

!""#$%&'#(#))*+#)#,+$-*.&%-*/#,0*12+03*4,%,*%2*)5662+%*7489)*+#:50,%2+;*3#$&)&2(*<,=&(:*
G" 9)3:8&'(-+/4&'+*/0*;
!"&%$(8.9%.&$#0*%.#/0,/:%-#$8/2#J&$%I&9%/$+&'($%)4%("&%2)*0#(8.#*/2%$(8.9%.&$#0*%4),%&Y+&.#(&.%,&-#&3;
Z#08,&%<;%

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
5. Cohort Identification  
 
5.1 Cohort Summary 
This study will involve a new user, parallel group, retrospective cohort study design comparing ticagrelor 90 mg twice daily to 
prasugrel 10 mg daily. The patients will be required to have continuous enrollment during the baseline period of 180 days before 
initiation of ticagrelor or prasugrel (index date). We will restrict the analyses to patients with an acute coronary syndrome, with 
or without ST-segment elevation, who were scheduled to undergo coronary angiography.  
 
5.2 Important steps for cohort formation 
New use of ticagrelor, exposure, and prasugrel comparator, is defined as no use of either therapy in 180 days prior to index date. 
 
 
5.2.1 Eligible cohort entry dates 
Market availability of ticagrelor in the U.S. started on 2011-07-20.       
• For Marketscan: 2011-07-20 to 2018-12-31 (end of data availability).  
• For Optum: 2011-07-20 to 2020-03-31 (end of data availability). 
 
5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date. Inclusion and exclusion criteria were 
adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in Appendix A and are 
summarized in the flowcharts below.   
 
5.3 Flowchart of the study cohort assembly 
 
  
Optum 
MarketScan 
  
Less 
Excluded 
Patients 
Remaining 
Patients 
Less 
Excluded 
Patients 
Remaining 
Patients 
All patients 
  
78,779,380 
  
200,203,908 
Parent: Did not meet cohort entry criteria 
-
78,582,029 
197,351 
-199978288 
225,620 
Parent: Excluded due to insufficient enrollment 
-27,693 
169,658 
-56919 
168,701 
Parent: Inclusion # 1.2.3 
-7,584 
162,074 
-17110 
151,591 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
 
 
6. 
Variables  
 
6.1 
Exposure-related 
variables:  
 
Study drug:  
The study exposure of 
interest is initiation of 
ticagrelor. Initiation will be 
defined as starting 
treatment with ticagrelor or 
a comparator drug with no 
prior use of the 
corresponding drug in the 
past 6 months (washout 
period).  
 
Comparator agents: 
New initiators of prasugrel 
10 mg, defined by no use of 
ticagrelor or prasugrel in the 
prior 6 months. 
 
 
6.2 Preliminary covariates: 
• Age 
• Sex 
Parent: Excluded based on Start of Prasgurel 10mg OR Ticagrelor 
90mg 
-139,539 
22,535 
-122209 
29,382 
Parent: Excluded based on Exclusion # 13 - PCI 
-1,511 
21,024 
-1228 
28,154 
Parent: Excluded based on Enrollment with allowed gap 
-16 
21,008 
-25 
28,129 
Parent: Final cohort 
  
21,008 
  
28,129 
Did not meet cohort entry criteria 
0 
21,008 
0 
28,129 
Excluded due to insufficient enrollment 
0 
21,008 
0 
28,129 
Excluded due to prior use of referent 
-325 
20,683 
-372 
27,757 
Excluded due to prior use of exposure 
-341 
20,342 
-535 
27,222 
Excluded because patient qualified in >1 exposure category 
-5 
20,337 
-3 
27,219 
Excluded based on Inclusion # 2 - Age ≥ 18 
0 
20,337 
0 
27,219 
Excluded based on Exclusion # 2 - history of stroke or TIA 
-6,788 
13,549 
-6784 
20,435 
Excluded based on Exclusion # 3 - intracranial neoplasm, 
intracranial AVM, intracranial aneurysm 
-15 
13,534 
-11 
20,424 
Excluded based on Exclusion # 4 - Active bleeding 
-446 
13,088 
-595 
19,829 
Excluded based on Exclusion # 6 - Thrombocytopenia 
-269 
12,819 
-261 
19,568 
Excluded based on Exclusion # 7 - Anemia 
-1,033 
11,786 
-891 
18,677 
Excluded based on Exclusion # 10 - chronic renal insufficiency 
-38 
11,748 
-37 
18,640 
Excluded based on Exclusion # 11 - Moderate/severe hepatic 
dysfunction 
-544 
11,204 
-578 
18,062 
Excluded based on Exclusion # 12 - Increased risk of bradycardia 
events 
-342 
10,862 
-413 
17,649 
Excluded based on Exclusion # 14 - CCI ≥ 10 
-24 
10,838 
-8 
17,641 
Excluded based on Exclusion # 15 - Concomitant therapy with 
strong CYP3A inhibitors/inducers 
-28 
10,810 
-53 
17,588 
Excluded based on Exclusion # 19 - Pregnancy 
-3 
10,807 
-6 
17,582 
Final cohort 
  
10,807 
  
17,582 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
• Combined Comorbidity Index (CCI), measured over the default baseline covariate assessment period, defined as 180 days 
prior to and including index date 
 
Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and analysis. 
We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between 
treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility 
analysis and the initial power assessment and are listed in Table 1 (Appendix B). 
 
6.3 Outcome variables and study follow-up:  
 
6.3.1 Outcome variables 
Primary effectiveness outcomes of interest (definitions provided in Appendix A):  
• Primary outcome: composite of death, myocardial infarction, or stroke at 1 year after randomization 
• Secondary outcomes: 
Individual components: 
o Hospital admission for MI  
o Hospital admission for stroke  
o Death 
 
Safety outcomes of interest: 
1. Major bleeding 
 
6.3.2 Study follow-up 
Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day 
of cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is 
the primary analysis, as it targets the relative hazard of outcomes on treatment.  
 
For the AT analyses, the follow-up will start the day after initiation of ticagrelor and comparator and will continue until the 
earliest date of the following events: 
• The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,  
• The date of end of continuous registration in the database, 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
•
End of the study period,
•
Measured death event occurs,
•
Nursing home admission
o
Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to
no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for
cohorts for the same reason.
•
The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (ticagrelor
and comparator) plus a defined grace period (i.e., 30 days after the end of the last prescription’s days’ supply in main
analyses).
•
The date of augmentation or switching from exposure to comparator or vice versa
•
The date of augmentation/switching from exposure or comparator to clopidogrel, measured as the initiation of clopidogrel
starting from 1 day after cohort entry date
o
A dosage change on the index treatment does not fulfill this criterion
o
An added treatment that is not part of the exposure or comparator group does not fulfill this criterion
For the ITT analyses, the censoring based on the augmentation/switching and treatment discontinuation will be replaced with a 
maximum allowed follow-up time of 365 days.  
7. Initial Feasibility Analysis
Aetion report links: 
Optum:  https://bwh-dope.aetion.com/projects/details/1740/rwrs/71503  
Marketscan: https://bwh-dope.aetion.com/projects/details/1739/rwrs/71505 
Date conducted: 06/11/2021 
Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the 
outcome. No measures of association will be computed nor will incidence rates stratified by treatment group.  

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
• Report patient characteristics by treatment group 
  
Optum 
Marketscan 
Variable 
Exposure - 
Ticagrelor 
(90 mg) 
Exposure - 
Prasugrel 
(10 mg) 
Difference 
Exposure - 
Ticagrelor 
(90 mg) 
Exposure - 
Prasugrel 
(10 mg) 
Difference 
Number of patients 
6,722 
4,085 
- (-, -) 
9,025 
8,557 
- (-, -) 
Age 
  
  
  
  
  
  
…mean (sd) 
63.60 (11.12) 
59.90 
(10.02) 
3.70 (3.29, 
4.11) 
58.41 (9.83) 
56.88 
(8.90) 
1.54 (1.26, 
1.81) 
…median [IQR] 
64.00 [56.00, 
71.00] 
60.00 
[53.00, 
67.00] 
- (-, -) 
59.00 [52.00, 
63.00] 
58.00 
[51.00, 
63.00] 
- (-, -) 
Gender 
  
  
  
  
  
  
…1 - Male; n (%) 
4,796 
(71.3%) 
3,152 
(77.2%) 
-5.8% (-
7.5%, -
4.1%) 
6,790 (75.2%) 
6,835 
(79.9%) 
-4.6% (-
5.9%, -
3.4%) 
…2 - Female; n (%) 
1,925 
(28.6%) 
933 
(22.8%) 
5.8% 
(4.1%, 
7.5%) 
2,235 (24.8%) 
1,722 
(20.1%) 
4.6% 
(3.4%, 
5.9%) 
CCI (180 days)- ICD9 and 
ICD10 
  
  
  
  
  
  
…mean (sd) 
1.51 (1.96) 
0.93 (1.74) 
0.58 (0.51, 
0.65) 
0.74 (1.54) 
0.50 (1.43) 
0.24 (0.19, 
0.28) 
…median [IQR] 
1.00 [0.00, 
3.00] 
1.00 [0.00, 
2.00] 
- (-, -) 
0.00 [0.00, 
2.00] 
0.00 [-1.00, 
1.00] 
- (-, -) 
 
• Report summary parameters of study population 
FEASIBILITY- FOR STUDY OUTCOME 
  
Optum 
Marketscan 
Variable 
Value 
Value 
Number of patients in full cohort 
10,807 
17,582 
Number of patients dropped as incomplete cases 
0 
0 
Number of patients that did not begin follow-up 
3 
5 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Number of patients in analytic cohort 
10,804 
17,577 
Number of events 
777 
1063 
Number of person-years 
7,415.55 
13,945.70 
Number of patients in group: Exposure - Ticagrelor (90 
mg) 
6,719 
9,021 
Number of patients in group: Exposure - Prasugrel (10 mg) 
4,085 
8,556 
Risk per 1,000 patients 
71.92 
60.48 
Rate per 1,000 person-years 
104.78 
76.22 
 
 
 
 
• Report median follow-up time by treatment group 
MEDIAN FOLLOW-UP TIME FOR STUDY OUTCOME 
Median Follow-Up Time (Days) [IQR] 
  
Optum 
Marketscan 
Patient Group 
Median Follow-Up Time 
(Days) [IQR] 
Median Follow-Up Time 
(Days) [IQR] 
Overall Patient Population 
196 [58, 391] 
249 [91, 420] 
Referent 
172 [58, 386] 
230 [85, 412] 
Exposure 
232 [81, 403] 
273 [109, 433] 
 
• Report reasons for censoring in the overall study population 
CENSORING REASONS FOR STUDY OUTCOME 
  
Optum 
Marketscan 
Overall 
  
  
Outcome 
368 (3.4%) 
516 (2.9%) 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Death 
0 (0.0%) 
0 (0.0%) 
Start of an additional exposure 
179 (1.7%) 
331 (1.9%) 
End of index exposure 
4,994 (46.2%) 
8,242 (46.9%) 
Specified date reached 
412 (3.8%) 
734 (4.2%) 
End of patient data 
0 (0.0%) 
0 (0.0%) 
End of patient enrollment 
1,873 (17.3%) 
4,889 (27.8%) 
Switch to clopidogrel + Nursing home admission 
2,978 (27.6%) 
2,865 (16.3%) 
•
Report overall risk of the primary outcome.
Optum 
Marketscan Pooled 
Risk per 1,000 patients 
71.92 
60.48 
64.81 
8. Initial Power Assessment
Aetion report links: 
Optum: https://bwh-dope.aetion.com/projects/details/1740/rwrs/71504  
Marketscan: https://bwh-dope.aetion.com/projects/details/1739/rwrs/71508 
Date conducted: 06/11/2021 
In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. 
Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined 
comorbidity index. Power calculations are based on the formulas from Chow et al. (2008). 
•
Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the
analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons
for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and
reported in the subsequent sections, after incorporating feedback and refining the protocol.

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
Pooled 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Superiority Analysis
Number of patients matched
24,266
Reference
12,133
Exposed
12,133
Risk per 1,000 patients
64.81
Desired HR from RCT
1.36
Alpha (2-sided)
0.05
Number of events expected
1572.67946
Power
0.999982406

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
 
Marketscan 
 
 
Optum 
Superiority Analysis
Number of patients matched
16,164
Reference
8,082
Exposed
8,082
Risk per 1,000 patients
60.48
Desired HR from RCT
1.36
Alpha (2-sided)
0.05
Number of events expected
977.59872
Power
0.997793559

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
•
Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of
advisory board.
Reviewed by PI: 
Date reviewed: 
Reviewed by FDA: 
Date reviewed: 
Reasons for stopping 
analysis (if required): 
9. Balance Assessment
Aetion report name: 
Optum: https://bwh-dope.aetion.com/projects/details/1740/rwrs/71506 
Marketscan: https://bwh-dope.aetion.com/projects/details/1739/rwrs/71510  
Date conducted: 06/10/2021 
Superiority Analysis
Number of patients matched
8,102
Reference
4,051
Exposed
4,051
Risk per 1,000 patients
71.92
Desired HR from RCT
1.36
Alpha (2-sided)
0.05
Number of events expected
582.69584
Power
0.960047459

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using 
the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the 
complete list of covariates. 
•
Provide plot of PS distributions stratified by treatment group.
Note- Please refer to Appendix B.
•
Report covariate balance after matching.
Note- For Table 1, please refer to Appendix B.
•
Report reasons for censoring by treatment group.
Overall 
Referent 
Exposure 
Dummy Outcome 
0 (0.00%) 
0 (0.00%) 
0 (0.00%) 
Death 
45 (0.31%) 
17 (0.23%) 
28 (0.38%) 
Start of an additional exposure 
307 (2.10%) 
248 (3.40%) 
59 (0.81%) 
End of index exposure 
8,472 (58.03%) 
4,309 (59.03%) 
4,163 (57.03%) 
Specified date reached 
602 (4.12%) 
245 (3.36%) 
357 (4.89%) 
End of patient enrollment 
3,773 (25.84%) 
1,714 (23.48%) 
2,059 (28.21%) 
Switch to clopidogrel + Nursing 
home admission 
1,401 (9.60%) 
767 (10.51%) 
634 (8.68%) 
•
Report follow-up time by treatment group.
Median Follow-Up Time (Days) [IQR] 
Patient Group 
Optum 
Marketscan 
Overall Patient Population 
208 [58-395] 
259 [99-430] 
Referent 
178 [58-391] 
241 [88-419] 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Exposure 
229 [80-402] 
286 [112-445] 
10. Final Power Assessment
Date conducted: 06/10/2021 
•
Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9.
All other parameters in the table should be the same as in Section 8.
Pooled
 
Marketscan 
Superiority Analysis
Number of patients matched
14,600
Reference
7,300
Exposed
7,300
Risk per 1,000 patients
65.52
Desired HR from RCT
1.36
Alpha (2-sided)
0.05
Number of events expected
956.592
Power
0.997405863

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
 
 
 
 
 
Optum 
Superiority Analysis
Number of patients matched
9,604
Reference
4,802
Exposed
4,802
Risk per 1,000 patients
61.61
Desired HR from RCT
1.36
Alpha (2-sided)
0.05
Number of events expected
591.70244
Power
0.962446362

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. 
Reviewed by PI: 
 
Date reviewed: 
 
Reviewed by FDA: 
 
Date reviewed: 
 
Reasons for stopping 
analysis (if required): 
 
 
11. Study Confidence and Concerns 
 
Deadline for voting on study confidence and listing concerns: 
Date votes and concerns are summarized:    
 
• If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps. 
• All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the 
success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may 
Superiority Analysis
Number of patients matched
4,996
Reference
2,498
Exposed
2,498
Risk per 1,000 patients
71.92
Desired HR from RCT
1.36
Alpha (2-sided)
0.05
Number of events expected
359.31232
Power
0.830035796

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study 
variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the 
individual respondent. 
•
After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here.
12. Register study protocol on clinicalTrials.gov
Date conducted: 
•
Register the study on clinicalTrials.gov and upload this document.
13. Comparative Analyses
Aetion report name: 
Date conducted:    
13.1 
For primary analysis:  
13.2 
For sensitivity analyses: 
14. Requested Results
14.1 
Table 1: Baseline characteristics before and after adjustment 
Variable 
Before adjustment 
After adjustment 
Referent 
Exposure 
Std. diff. 
Referent 
Exposure 
Std. diff. 
Number of patients 
- 
- 
Age categories 
… 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
14.2 
Table 2: Follow-up time 
Patient Group 
Median Follow-Up Time (Days) [IQR] 
Overall Patient Population 
Referent 
Exposure 
14.3 
Table 3: Censoring events 
Overall 
Referent 
Exposure 
Outcome 
Death 
Start of an additional exposure 
End of index exposure 
Specified date reached 
End of patient data 
End of patient enrollment 
… 
14.4 
Table 4: Results from primary analyses; 
Analysis 
No. exposed events 
No. referent events 
Exposed rate 
Referent rate 
HR (95% CI) 
Crude 
Analysis 1 
Analysis 2 
... 
HR, Hazard Ratio; CI, Confidence Interval. 
14.5 
Table 5: Results from secondary analyses; 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
15. References
Schupke S., Neumann F., Menichelli M., et al. Ticagrelor or Prasugrel in Patients 
with Acute Coronary Syndromes. N Engl J Med. 2019; 381:1524-1534 
Chow S, Shao J, Wang H. 2008.  Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 
177 

Trial Name (with web links) ISAR-REACT 5
Trial Name (with pdf links)
ISAR-REACT 5
NCT 
NCT01944800
Therapeutic Area
Cardiology/Vascular Diseases
Study Batch
Antiplatelets
Brand Name
Brilinta
Generic Name
Ticagrelor
Sponsor
Deutsches Herzzentrum Muenchen
Year
2019
Measurable Endpoint
The primary end point was the composite of
stroke, myocardial infarction, or death
Exposure
Ticagrelor
Comparator
Prasugrel
Population
Patients who were hospitalized for an acute coronary syndrome (ST-segment 
elevation myocardial infarction, non-ST-segment elevation myocardial 
infarction or unstable angina pectoris) with planned invasive strategy
Trial Finding
HR = 1.36 (95% CI, 1.09 to 1.70)
 No. of Patients 
4,018 (2,012 in exposed arm)
Power
80% power; 1895 patients in each group would be needed for the trial to detect 
a relative risk
that was lower by 22.5% in the rate of the primary end point in the ticagrelor 
group as compared with the prasugrel group
Appendix A

Coronary angiography
Procedure codes any diagnosis position, inpatient and outpatient setting
CPT
93451 performed
93452
 Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging 
supervision and interpretation, when performed
93453
 Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography, 
imaging supervision and interpretation, when performed
93454 Coronary angiography
93455 Coronary angiography with bypass grafts
93456 Coronary angiography with right heart catheterization
93457 Coronary angiography and bypass grafts, with right heart catheterization
93458 Coronary angiography with left heart catheterization
93459 Coronary angiography and bypass grafts, with left heart catheterization
93460 Coronary angiography with right and left heart catheterization
93461 Coronary angiography with bypass grafts, right and left heart catheterization
93563 Injection/imaging for coronary angiography with cath for congenital anomaly
93564 Injection/imaging for bypass graft angiography with cath for congenital anomaly
93565 Injection/imaging for left heart angiography with cath for congenital anomaly
93566 Injection/imaging for right heart angiography with cath for congenital anomaly
75574
Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with 
contrast material, including 3D image postprocessing (including evaluation of cardiac structure and 
morphology, assessment of cardiac function, and evaluation of venous structures, if performed)
ICD-9 PX
37.21 Right heart cardiac catheterization
37.22 Left heart cardiac catheterization
37.23 Combined right and left heart cardiac catheterization
ICD 10 PX
Source : https://www.cordis.com/content/dam/cordis/web/documents/fact-sheet/cordis-cardiology-reimbursement-fact-
Appendix A

B21 
 Fluoroscopy (heart)
B210xxx
 Coronary Artery, Single
B211xxx
 Coronary Arteries, Multiple
B212xxx
 Coronary Artery Bypass Graft, Single
B213xxx
 Coronary Artery Bypass Grafts, Multiple
B214xxx
 Heart, Right
B215xxx
 Heart, Left
B216xxx
 Heart, Right and Left
B217xxx
 Internal Mammary Bypass Graft, Right
B218xxx
 Internal Mammary Bypass Graft, Left
B21Fxxx
 Bypass Graft, Other
B22
CT Scan (heart)
B221xxx
 Coronary Arteries, Multiple
B223xxx
 Coronary Artery Bypass Grafts, Multiple
B226xxx
 Heart, Right and Left
B31
Fluoroscopy (upper arteries)
B312xxx
 Subclavian Artery, Left
B313xxx
 Common Carotid Artery, Right
B314xxx
 Common Carotid Artery, Left
B315xxx
 Common Carotid Arteries, Bilateral
B316xxx
 Internal Carotid Artery, Right
B317xxx
 Internal Carotid Artery, Left
B318xxx
 Internal Carotid Arteries, Bilateral
B319xxx
 External Carotid Artery, Right
B31Bxxx
 External Carotid Artery, Left
B31Cxxx
 External Carotid Arteries, Bilateral
B32
CT scan (upper arteries)
B325xxx
 Common Carotid Arteries, Bilateral
B328xxx
 Internal Carotid Arteries, Bilateral
Appendix A

Major bleeding exclusion criteria: 1 inpatient (any position) or 2 outpatient diagnosis (separated by 7-365 days)
562.02
 (ICD9) DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.03
 (ICD9) DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.12
 (ICD9) DIVERTICULOSIS OF COLON WITH HEMORRHAGE
562.13
 (ICD9) DIVERTICULITIS OF COLON WITH HEMORRHAGE
568.81
 (ICD9) HEMOPERITONEUM (NONTRAUMATIC)
569.3
 (ICD9) HEMORRHAGE OF RECTUM AND ANUS
569.83
 (ICD9) PERFORATION OF INTESTINE
569.85
 (ICD9) ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
569.86
 (ICD9) DIEULAFOY LESION (HEMORRHAGIC) OF INTESTINE
578
 (ICD9) HEMATEMESIS
578.9
 (ICD9) HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
423
 (ICD9) HEMOPERICARDIUM
432
 (ICD9) NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1
 (ICD9) SUBDURAL HEMORRHAGE
432.9
 (ICD9) UNSPECIFIED INTRACRANIAL HEMORRHAGE
459
 (ICD9) HEMORRHAGE UNSPECIFIED
531
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE
531
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.01
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.2
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.41
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 
WITHOUT OBSTRUCTION
Appendix A

531.61
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH 
OBSTRUCTION
532
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE
532
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.2
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT 
OBSTRUCTION
532.21
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.4
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT 
OBSTRUCTION
532.41
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.6
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 
WITHOUT OBSTRUCTION
532.61
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 
WITH OBSTRUCTION
533
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.2
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
WITHOUT OBSTRUCTION
533.21
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH 
OBSTRUCTION
533.4
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.4
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 
WITHOUT OBSTRUCTION
533.41
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH 
OBSTRUCTION
Appendix A

533.6
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND 
PERFORATION
533.6
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND 
PERFORATION WITHOUT OBSTRUCTION
533.61
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND 
PERFORATION WITH OBSTRUCTION
534
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.01
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.2
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.2
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT 
OBSTRUCTION
534.21
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH 
OBSTRUCTION
534.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT 
OBSTRUCTION
534.41
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH 
OBSTRUCTION
534.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND 
PERFORATION
534.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND 
PERFORATION WITHOUT OBSTRUCTION
534.61
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND 
PERFORATION WITH OBSTRUCTION
578.1
 (ICD9) BLOOD IN STOOL
719.1
 (ICD9) HEMARTHROSIS
719.1
 (ICD9) HEMARTHROSIS SITE UNSPECIFIED
719.11
 (ICD9) HERARTHROSIS INVOLVING SHOULDER REGION
719.12
 (ICD9) HEMARTHORSIS INVOLVING UPPER ARM
719.13
 (ICD9) HEMARTHROSIS INVOLVING FOREARM
Appendix A

719.14
 (ICD9) HEMARTHROSIS INVOLVING HAND
719.15
 (ICD9) HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.16
 (ICD9) HEMARTHROSIS INVOLVING LOWER LEG
719.17
 (ICD9) HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.18
 (ICD9) HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
719.19
 (ICD9) HEMARTHROSIS INVOLVING MULTIPLE SITES
430
 (ICD9) SUBARACHNOID HEMORRHAGE
431
 (ICD9) INTRACEREBRAL HEMORRHAGE
I31.2 
 (ICD10) Hemopericardium, not elsewhere classified
I60.00 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.11 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2 
 (ICD10) Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.30 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.31 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4 
 (ICD10) Nontraumatic subarachnoid hemorrhage from basilar artery
I60.50 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.51 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6 
 (ICD10) Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.7 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8 
 (ICD10) Other nontraumatic subarachnoid hemorrhage
I60.9 
 (ICD10) Nontraumatic subarachnoid hemorrhage, unspecified
I61.0 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.2 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3 
 (ICD10) Nontraumatic intracerebral hemorrhage in brain stem
Appendix A

I61.4 
 (ICD10) Nontraumatic intracerebral hemorrhage in cerebellum
I61.5 
 (ICD10) Nontraumatic intracerebral hemorrhage, intraventricular
I61.6 
 (ICD10) Nontraumatic intracerebral hemorrhage, multiple localized
I61.8 
 (ICD10) Other nontraumatic intracerebral hemorrhage
I61.9 
 (ICD10) Nontraumatic intracerebral hemorrhage, unspecified
I62.00 
 (ICD10) Nontraumatic subdural hemorrhage, unspecified
I62.01 
 (ICD10) Nontraumatic acute subdural hemorrhage
I62.02 
 (ICD10) Nontraumatic subacute subdural hemorrhage
I62.03 
 (ICD10) Nontraumatic chronic subdural hemorrhage
I62.1 
 (ICD10) Nontraumatic extradural hemorrhage
I62.9 
 (ICD10) Nontraumatic intracranial hemorrhage, unspecified
K25.0 
 (ICD10) Acute gastric ulcer with hemorrhage
K25.2 
 (ICD10) Acute gastric ulcer with both hemorrhage and perforation
K25.4 
 (ICD10) Chronic or unspecified gastric ulcer with hemorrhage
K25.6 
 (ICD10) Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0 
 (ICD10) Acute duodenal ulcer with hemorrhage
K26.2 
 (ICD10) Acute duodenal ulcer with both hemorrhage and perforation
K26.4 
 (ICD10) Chronic or unspecified duodenal ulcer with hemorrhage
K26.6 
 (ICD10) Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0 
 (ICD10) Acute peptic ulcer, site unspecified, with hemorrhage
K27.2 
 (ICD10) Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.4 
 (ICD10) Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.6 
 (ICD10) Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0 
 (ICD10) Acute gastrojejunal ulcer with hemorrhage
K28.2 
 (ICD10) Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.4 
 (ICD10) Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6 
 (ICD10) Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K55.21 
 (ICD10) Angiodysplasia of colon with hemorrhage
K56.60 
 (ICD10) Unspecified intestinal obstruction
K57.01 
 (ICD10) Diverticulitis of small intestine with perforation and abscess with bleeding
K57.11 
 (ICD10) Diverticulosis of small intestine without perforation or abscess with bleeding
Appendix A

K57.13 
 (ICD10) Diverticulitis of small intestine without perforation or abscess with bleeding
K57.21 
 (ICD10) Diverticulitis of large intestine with perforation and abscess with bleeding
K57.31 
 (ICD10) Diverticulosis of large intestine without perforation or abscess with bleeding
K57.33 
 (ICD10) Diverticulitis of large intestine without perforation or abscess with bleeding
K57.41 
 (ICD10) Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.51 
 (ICD10) Diverticulosis of both small and large intestine without perforation or abscess with 
bleeding
K57.53 
 (ICD10) Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.81 
 (ICD10) Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91 
 (ICD10) Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93 
 (ICD10) Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5 
 (ICD10) Hemorrhage of anus and rectum
K63.1 
 (ICD10) Perforation of intestine (nontraumatic)
K63.81 
 (ICD10) Dieulafoy lesion of intestine
K66.1 
 (ICD10) Hemoperitoneum
K92.0 
 (ICD10) Hematemesis
K92.1 
 (ICD10) Melena
K92.2 
 (ICD10) Gastrointestinal hemorrhage, unspecified
M25.00 
 (ICD10) Hemarthrosis, unspecified joint
M25.011 
 (ICD10) Hemarthrosis, right shoulder
M25.012 
 (ICD10) Hemarthrosis, left shoulder
M25.019 
 (ICD10) Hemarthrosis, unspecified shoulder
M25.021 
 (ICD10) Hemarthrosis, right elbow
M25.022 
 (ICD10) Hemarthrosis, left elbow
M25.029 
 (ICD10) Hemarthrosis, unspecified elbow
M25.031 
 (ICD10) Hemarthrosis, right wrist
M25.032 
 (ICD10) Hemarthrosis, left wrist
M25.039 
 (ICD10) Hemarthrosis, unspecified wrist
M25.041 
 (ICD10) Hemarthrosis, right hand
M25.042 
 (ICD10) Hemarthrosis, left hand
M25.049 
 (ICD10) Hemarthrosis, unspecified hand
Appendix A

M25.051 
 (ICD10) Hemarthrosis, right hip
M25.052 
 (ICD10) Hemarthrosis, left hip
M25.059 
 (ICD10) Hemarthrosis, unspecified hip
M25.061 
 (ICD10) Hemarthrosis, right knee
M25.062 
 (ICD10) Hemarthrosis, left knee
M25.069 
 (ICD10) Hemarthrosis, unspecified knee
M25.071 
 (ICD10) Hemarthrosis, right ankle
M25.072 
 (ICD10) Hemarthrosis, left ankle
M25.073 
 (ICD10) Hemarthrosis, unspecified ankle
M25.074 
 (ICD10) Hemarthrosis, right foot
M25.075 
 (ICD10) Hemarthrosis, left foot
M25.076 
 (ICD10) Hemarthrosis, unspecified foot
M25.08 
 (ICD10) Hemarthrosis, other specified site
R58 
 (ICD10) Hemorrhage, not elsewhere classified
R04 
 (ICD10) Hemorrhage from respiratory passages
R04.0 
 (ICD10) Epistaxis
R04.1 
 (ICD10) Hemorrhage from throat
R04.2 
 (ICD10) Hemoptysis
R04.8 
 (ICD10) Hemorrhage from other sites in respiratory passages
R04.81 
 (ICD10) Acute idiopathic pulmonary hemorrhage in infants
R04.89 
 (ICD10) Hemorrhage from other sites in respiratory passages
R04.9 
 (ICD10) Hemorrhage from respiratory passages, unspecified
R31 
 (ICD10) Hematuria
R31.0 
 (ICD10) Gross hematuria
R31.1 
 (ICD10) Benign essential microscopic hematuria
R31.2 
 (ICD10) Other microscopic hematuria
R31.21
R31.29
R31.9 
 (ICD10) Hematuria, unspecified
784.7
 (ICD9) EPISTAXIS
784.8
 (ICD9) HEMORRHAGE FROM THROAT
Appendix A

599.7
 (ICD9) HEMATURIA
599.7
 (ICD9) HEMATURIA UNSPECIFIED
599.71
 (ICD9) GROSS HEMATURIA
599.72
 (ICD9) MICROSCOPIC HEMATURIA
786.3
 (ICD9) HEMOPTYSIS
786.3
 (ICD9) HEMOPTYSIS UNSPECIFIED
786.31
 (ICD9) ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS
786.39
 (ICD9) OTHER HEMOPTYSIS
The occurrence of Inpatient with the following attributes:
Legacy Attribute  Procedure Code (Any Position) is any of: { “44.43”, “43255”, “0W3P8ZZ” }
44.43
 (ICD9) ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING
43255
 (HCPCS) Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method / 
Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or 
jejunum as appropriate; with control of bleeding, any method
0W3P8ZZ 
 (ICD10) Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic
Appendix A

PCI
Procedure codes in any position, inpatient or outpatient setting
HCPCS/CPT codes:
92925
 (HCPCS) Percutaneous transluminal coronary atherectomy, with coronary angioplasty when 
performed; each additional branch of a major coronary artery (List separately in addition to 
code for primary procedure)
92920
 (HCPCS) Percutaneous transluminal coronary angioplasty; single major coronary artery or 
branch
92921
 (HCPCS) Percutaneous transluminal coronary angioplasty; each additional branch of a major 
coronary artery (List separately in addition to code for primary procedure)
92924
 (HCPCS) Percutaneous transluminal coronary atherectomy, with coronary angioplasty when 
performed; single major coronary artery or branch
92929
 (HCPCS) Percutaneous transcatheter placement of intracoronary stent(s), with coronary 
angioplasty when performed; each additional branch of a major coronary artery (List 
separately in addition to code for primary procedure)
92933
 (HCPCS) Percutaneous transluminal coronary atherectomy, with intracoronary stent, with 
coronary angioplasty when performed; single major coronary artery or branch
92934
 (HCPCS) Percutaneous transluminal coronary atherectomy, with intracoronary stent, with 
coronary angioplasty when performed; each additional branch of a major coronary artery 
(List separately in addition to code for primary procedure)
92928
 (HCPCS) Percutaneous transcatheter placement of intracoronary stent(s), with coronary 
angioplasty when performed; single major coronary artery or branch
ICD-9 px codes:
0.66
 (ICD9) PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [PTCA]
36.09
 (ICD9) OTHER REMOVAL OF CORONARY ARTERY OBSTRUCTION
36.06
 (ICD9) INSERTION OF NON
36.07
 (ICD9) INSERTION OF DRUG
ICD-10 px codes:
027004Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Drug
Appendix A

027005Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Two Drug
02700GZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, 
Open Approach
027035Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Two Drug
027037Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Four or More Drug
02703EZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, 
Percutaneous Approach
02703FZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, 
Percutaneous Approach
270456
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug
027045Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Two Drug
027046Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Three Drug
02704DZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous 
Endoscopic Approach
2.70E+09
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, 
Percutaneous Endoscopic Approach
02704G6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal 
Devices, Percutaneous Endoscopic Approach
02704TZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, 
Percutaneous Endoscopic Approach
027104Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Drug
027105Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Two Drug
271066
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug
02710GZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, 
Open Approach
271466
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug
02714FZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, 
Percutaneous Endoscopic Approach
02714Z6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic 
Approach
027205Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Two Drug
Appendix A

272346
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug
027235Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Two Drug
272366
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug
02723EZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, 
Percutaneous Approach
272446
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug
027244Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Drug
272476
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug
02724FZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, 
Percutaneous Endoscopic Approach
02730DZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open 
Approach
02730FZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, 
Open Approach
02730TZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal 
Device, Open Approach
273346
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug
02733FZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, 
Percutaneous Approach
02733TZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal 
Device, Percutaneous Approach
273446
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug
273476
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More 
Drug
02734EZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, 
Percutaneous Endoscopic Approach
02C04Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous 
Endoscopic Approach
02C04ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic 
Approach
Appendix A

02C23ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach
02C24Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, 
Percutaneous Endoscopic Approach
02C33Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, 
Percutaneous Approach
02C33ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous 
Approach
02700G6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal 
Devices, Open Approach
02700TZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open 
Approach
270346
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Drug
027034Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Drug
270356
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug
02703D6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, 
Percutaneous Approach
02703TZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, 
Percutaneous Approach
027044Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Drug
02704D6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, 
Percutaneous Endoscopic Approach
2.71E+09
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal 
Devices, Open Approach
02710EZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open 
Approach
02710FZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open 
Approach
027134Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Drug
02713D6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, 
Percutaneous Approach
Appendix A

02713EZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, 
Percutaneous Approach
02713TZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, 
Percutaneous Approach
02713ZZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Percutaneous Approach
027147Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Drug
02714GZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, 
Percutaneous Endoscopic Approach
027204Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Drug
272056
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug
02720FZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open 
Approach
02720TZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, 
Open Approach
027237Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Drug
02723FZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, 
Percutaneous Approach
027245Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Two Drug
272466
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug
027246Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Three Drug
02724Z6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic 
Approach
273046
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug
273076
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More 
Drug
273366
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug
027337Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Drug
02733T6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Approach
02733Z6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous 
Approach
Appendix A

027344Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Drug
027346Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Drug
02734D6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal 
Device, Percutaneous Endoscopic Approach
02734DZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, 
Percutaneous Endoscopic Approach
02734F6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three 
Intraluminal Devices, Percutaneous Endoscopic Approach
02734TZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal 
Device, Percutaneous Endoscopic Approach
02C03Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous 
Approach
270066
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug
027007Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Four or More Drug
02700D6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open 
Approach
02700DZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach
2.70E+09
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, 
Open Approach
02700EZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open 
Approach
02700F6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal 
Devices, Open Approach
02700FZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open 
Approach
027036Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Three Drug
2.70E+09
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, 
Percutaneous Approach
270466
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug
270476
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug
Appendix A

02704EZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, 
Percutaneous Endoscopic Approach
02704FZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, 
Percutaneous Endoscopic Approach
271046
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug
271076
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug
02710F6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal 
Devices, Open Approach
02710T6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Open Approach
271356
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug
027135Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Two Drug
02713Z6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach
271456
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug
02714D6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, 
Percutaneous Endoscopic Approach
02714F6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal 
Devices, Percutaneous Endoscopic Approach
02714T6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach
027206Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Three Drug
027207Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Drug
02720DZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open 
Approach
2.72E+09
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal 
Devices, Open Approach
02720EZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open 
Approach
02720GZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, 
Open Approach
Appendix A

02720T6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Open Approach
027234Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Drug
02723D6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, 
Percutaneous Approach
02723DZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous 
Approach
027247Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Drug
02724F6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal 
Devices, Percutaneous Endoscopic Approach
02724T6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach
02724TZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, 
Percutaneous Endoscopic Approach
02724ZZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach
273056
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug
273066
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug
02730D6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal 
Device, Open Approach
02730T6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Open Approach
273356
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug
02733DZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, 
Percutaneous Approach
2.73E+09
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two 
Intraluminal Devices, Percutaneous Approach
027345Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Drug
02734GZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal 
Devices, Percutaneous Endoscopic Approach
02734ZZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic 
Approach
Appendix A

02C14ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic 
Approach
02700T6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal 
Device, Open Approach
270366
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug
270376
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug
02703DZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous 
Approach
02703GZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, 
Percutaneous Approach
02703Z6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach
02703ZZ 
 (ICD10) Dilation of Coronary Artery, One Artery, Percutaneous Approach
270446
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Drug
02704GZ 
 (ICD10) Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, 
Percutaneous Endoscopic Approach
02704T6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal 
Device, Percutaneous Endoscopic Approach
02704ZZ 
 (ICD10) Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach
027107Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Drug
02710DZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach
02710TZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, 
Open Approach
271346
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug
271376
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug
027137Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Drug
2.71E+09
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal 
Devices, Percutaneous Approach
271446
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug
027146Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Three Drug
Appendix A

02714DZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous 
Endoscopic Approach
02714G6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Percutaneous Endoscopic Approach
02714TZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, 
Percutaneous Endoscopic Approach
272046
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug
272066
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug
02720D6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, 
Open Approach
02720G6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Open Approach
027236Z 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Three Drug
02723GZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, 
Percutaneous Approach
02723TZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, 
Percutaneous Approach
02723Z6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach
02724D6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, 
Percutaneous Endoscopic Approach
2.72E+09
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal 
Devices, Percutaneous Endoscopic Approach
02724GZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, 
Percutaneous Endoscopic Approach
027306Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Drug
027307Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Drug
02730EZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, 
Open Approach
02730F6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three 
Intraluminal Devices, Open Approach
Appendix A

02730G6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Open Approach
027334Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Drug
027335Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Drug
273376
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More 
Drug
02733EZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, 
Percutaneous Approach
02733F6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three 
Intraluminal Devices, Percutaneous Approach
273456
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug
2.73E+09
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two 
Intraluminal Devices, Percutaneous Endoscopic Approach
02C23Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, 
Percutaneous Approach
270046
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Drug
270056
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug
027006Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Three Drug
270076
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug
02703F6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal 
Devices, Percutaneous Approach
02703G6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal 
Devices, Percutaneous Approach
02703T6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal 
Device, Percutaneous Approach
027047Z 
 (ICD10) Dilation of Coronary Artery, One Artery with Four or More Drug
02704F6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal 
Devices, Percutaneous Endoscopic Approach
02704Z6 
 (ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic 
Approach
271056
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug
Appendix A

027106Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Three Drug
02710D6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, 
Open Approach
02710G6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Open Approach
271366
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug
027136Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Three Drug
02713DZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous 
Approach
02713F6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal 
Devices, Percutaneous Approach
02713FZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, 
Percutaneous Approach
02713G6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Percutaneous Approach
02713GZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, 
Percutaneous Approach
02713T6 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Approach
027144Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Drug
027145Z 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Two Drug
271476
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug
2.71E+09
 (ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal 
Devices, Percutaneous Endoscopic Approach
02714EZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, 
Percutaneous Endoscopic Approach
02714ZZ 
 (ICD10) Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach
272076
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug
02720F6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal 
Devices, Open Approach
272356
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug
Appendix A

272376
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug
2.72E+09
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal 
Devices, Percutaneous Approach
02723F6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal 
Devices, Percutaneous Approach
02723G6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Percutaneous Approach
02723T6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Approach
02723ZZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Percutaneous Approach
272456
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug
02724DZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous 
Endoscopic Approach
02724EZ 
 (ICD10) Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, 
Percutaneous Endoscopic Approach
02724G6 
 (ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Percutaneous Endoscopic Approach
027304Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Drug
027305Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Drug
2.73E+09
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two 
Intraluminal Devices, Open Approach
02730GZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal 
Devices, Open Approach
027336Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Drug
02733D6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal 
Device, Percutaneous Approach
02733G6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Percutaneous Approach
02733GZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal 
Devices, Percutaneous Approach
02733ZZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach
Appendix A

273466
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug
027347Z 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Drug
02734FZ 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, 
Percutaneous Endoscopic Approach
02734G6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More 
Intraluminal Devices, Percutaneous Endoscopic Approach
02734T6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach
02734Z6 
 (ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous 
Endoscopic Approach
02C03ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach
02C13Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, 
Percutaneous Approach
02C13ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach
02C14Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, 
Percutaneous Endoscopic Approach
02C24ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous 
Endoscopic Approach
02C34Z6 
 (ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, 
Percutaneous Endoscopic Approach
02C34ZZ 
 (ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous 
Endoscopic Approach
Appendix A

Title
Pregnancy
ICD-9 Dx inpatient any position
650
Normal delivery
660
Obstructed labor
661
Abnormality of forces of labor
662
Long labor
663
Umbilical cord complications during labor and delivery
664
Trauma to perneum and vulva during delivery
665
Other obstetrical trauma
667
Retained placenta or membranes without hemorrhage
668
Complications of the administration of anesthetic or other sedation in labor and 
delivery
669.94
Unspecified complication of labor and delivery postpartum condition or 
complication
V24
Postpartum care and examination
V24.0
Postpartum care and examination immediately after delivery
V24.1
Postpartum care and examination of lactating mother
V24.2
Routine postpartum follow
V27
Outcome of delivery
V27.0
Mother with single liveborn
V27.1
Mother with single stillborn
V27.2
Mother with twins both liveborn
V27.3
Mother with twins one liveborn and one stillborn
V27.4
Mother with twins both stillborn
V27.5
Mother with other multiple birth all liveborn
V27.6
Mother with other multiple birth some liveborn
V27.7
Mother with other multiple birth all stillborn
V27.9
Mother with unspecified outcome of delivery
Appendix A

ICD-9 Px inpatient any position
72.0
Low forceps operation
72.1
Low forceps operation with episiotomy
72.2
Mid forceps operation
72.21
Mid forceps operation with episiotomy
72.29
Other mid forceps operation
72.3
High forceps operation
72.31
High forceps operation with episiotomy
72.39
Other high forceps operation
72.4
Forceps rotation of fetal head
72.5
Breech extraction
72.51
Partial breech extraction with forceps to aftercoming head
72.52
Other partial breech extraction
72.53
Total breech extraction with forceps to aftercoming head
72.54
Other total breech extraction
72.6
Forceps application to aftercoming head
72.7
Vacuum extraction
72.71
Vacuum extraction with episiotomy
72.79
Other vacuum extraction
72.8
Other specified instrumental delivery
72.9
Unspecified instrumental delivery
73.0
Artificial rupture of membranes
73.01
Induction of labor by artificial rupture of membranes
73.09
Other artificial rupture of membranes
73.1
Other surgical induction of labor
73.2
Internal and combined version and extraction
73.21
Internal and combined version without extraction
73.22
Internal and combined version with extraction
73.3
Failed forceps
73.4
Medical induction of labor
73.5
Manually assisted delivery
Appendix A

73.51
Manual rotation of fetal head
73.59
Other manually assisted delivery
73.6
Episiotomy
73.8
Operations on fetus to facilitate delivery
73.9
Other operations assisting delivery
73.91
External version assisting delivery
73.92
Replacement of prolapsed umbilical cord
73.93
Incision of cervix to assist delivery
73.94
Pubiotomy to assist delivery
73.99
Other operations assisting delivery
74.0
Classical cesarean section
74.1
Low cervical cesarean section
74.2
Extraperitoneal cesarean section
74.3
Removal of extratubal ectopic pregnancy
74.4
Cesarean section of other specified type
74.9
Cesarean section of unspecified type
74.91
Hysterotomy to terminate pregnancy
74.99
Other cesarean section of unspecified type
75.4
Manual removal of retained placenta
75.5
Repair of current obstetric laceration of uterus
75.6
Repair of other current obstetric laceration
75.7
Manual exploration of uterine cavity, postpartum
75.9
Other obstetric operations
Appendix A

AFTER PS MATCHING
Optum
MarketScan
BEFORE PS MATCHING
The c-statistics for the propensity score model, pre-matching was
0.811. The post-matching c-statistic was 0.562.
The c-statistics for the propensity score model, pre-matching was
0.795. The post-matching c-statistic was 0.535.
Appendix B

Ticagrelor
Prasugrel
St. Diff
Ticagrelor
Prasugrel
St. Diff
Ticagrelor
Prasugrel
St. Diff
Number of patients
6,722
4,085
9,025
8,557
 15,747 
 12,642 
Quarter/Year of Cohort Entry Date
...Q3 2011; n (%)
1 (0.0%)
169 (4.1%)
-0.2924
2 (0.0%)
478 (5.6%)
-0.3444
003 (0.0%)
647 (5.1%)
-0.328
...Q4 2011; n (%)
2 (0.0%)
195 (4.8%)
-0.3176
19 (0.2%)
644 (7.5%)
-0.3864
021 (0.1%)
839 (6.6%)
-0.367
...Q1 2012; n (%)
11 (0.2%)
165 (4.0%)
-0.2674
51 (0.6%)
695 (8.1%)
-0.3741
062 (0.4%)
860 (6.8%)
-0.349
...Q2 2012; n (%)
30 (0.4%)
187 (4.6%)
-0.2715
104 (1.2%)
607 (7.1%)
-0.2991
134 (0.9%)
794 (6.3%)
-0.293
...Q3 2012; n (%)
44 (0.7%)
181 (4.4%)
-0.2363
142 (1.6%)
621 (7.3%)
-0.2791
186 (1.2%)
802 (6.3%)
-0.271
...Q4 2012; n (%)
42 (0.6%)
177 (4.3%)
-0.2411
177 (2.0%)
557 (6.5%)
-0.2245
219 (1.4%)
734 (5.8%)
-0.238
...Q1 2013; n (%)
80 (1.2%)
168 (4.1%)
-0.1813
172 (1.9%)
373 (4.4%)
-0.1435
252 (1.6%)
541 (4.3%)
-0.160
...Q2 2013; n (%)
95 (1.4%)
143 (3.5%)
-0.1362
196 (2.2%)
302 (3.5%)
-0.0782
291 (1.8%)
445 (3.5%)
-0.106
...Q3 2013; n (%)
75 (1.1%)
147 (3.6%)
-0.1656
255 (2.8%)
376 (4.4%)
-0.0860
330 (2.1%)
523 (4.1%)
-0.116
...Q4 2013; n (%)
82 (1.2%)
139 (3.4%)
-0.1472
275 (3.0%)
315 (3.7%)
-0.0389
357 (2.3%)
454 (3.6%)
-0.077
...Q1 2014; n (%)
81 (1.2%)
122 (3.0%)
-0.1258
245 (2.7%)
296 (3.5%)
-0.0462
326 (2.1%)
418 (3.3%)
-0.074
...Q2 2014; n (%)
92 (1.4%)
126 (3.1%)
-0.1148
319 (3.5%)
301 (3.5%)
0.0000
411 (2.6%)
427 (3.4%)
-0.047
...Q3 2014; n (%)
109 (1.6%)
117 (2.9%)
-0.0877
399 (4.4%)
312 (3.6%)
0.0408
508 (3.2%)
429 (3.4%)
-0.011
...Q4 2014; n (%)
109 (1.6%)
117 (2.9%)
-0.0877
430 (4.8%)
297 (3.5%)
0.0652
539 (3.4%)
414 (3.3%)
0.006
...Q1 2015; n (%)
92 (1.4%)
87 (2.1%)
-0.0534
335 (3.7%)
190 (2.2%)
0.0887
427 (2.7%)
277 (2.2%)
0.032
...Q2 2015; n (%)
102 (1.5%)
78 (1.9%)
-0.0309
354 (3.9%)
166 (1.9%)
0.1194
456 (2.9%)
244 (1.9%)
0.065
...Q3 2015; n (%)
110 (1.6%)
96 (2.4%)
-0.0572
436 (4.8%)
191 (2.2%)
0.1418
546 (3.5%)
287 (2.3%)
0.072
...Q4 2015; n (%)
130 (1.9%)
124 (3.0%)
-0.0712
483 (5.4%)
234 (2.7%)
0.1373
613 (3.9%)
358 (2.8%)
0.061
...Q1 2016; n (%)
117 (1.7%)
129 (3.2%)
-0.0971
462 (5.1%)
247 (2.9%)
0.1124
579 (3.7%)
376 (3.0%)
0.039
...Q2 2016; n (%)
170 (2.5%)
118 (2.9%)
-0.0247
497 (5.5%)
231 (2.7%)
0.1416
667 (4.2%)
349 (2.8%)
0.076
...Q3 2016; n (%)
199 (3.0%)
130 (3.2%)
-0.0115
534 (5.9%)
232 (2.7%)
0.1582
733 (4.7%)
362 (2.9%)
0.094
...Q4 2016; n (%)
213 (3.2%)
133 (3.3%)
-0.0056
576 (6.4%)
225 (2.6%)
0.1841
789 (5.0%)
358 (2.8%)
0.114
...Q1 2017; n (%)
276 (4.1%)
113 (2.8%)
0.0713
524 (5.8%)
158 (1.8%)
0.2104
800 (5.1%)
271 (2.1%)
0.162
...Q2 2017; n (%)
411 (6.1%)
122 (3.0%)
0.1492
578 (6.4%)
162 (1.9%)
0.2271
989 (6.3%)
284 (2.2%)
0.204
...Q3 2017; n (%)
490 (7.3%)
125 (3.1%)
0.1900
693 (7.7%)
192 (2.2%)
0.2556
1,183 (7.5%)
317 (2.5%)
0.231
...Q4 2017; n (%)
578 (8.6%)
122 (3.0%)
0.2413
756 (8.4%)
154 (1.8%)
0.3034
1,334 (8.5%)
276 (2.2%)
0.283
...Q1 2018; n (%)
535 (8.0%)
96 (2.4%)
0.2543
11 (0.1%)
1 (0.0%)
0.0447
546 (3.5%)
097 (0.8%)
0.187
Demographics
Age
...mean (sd)
63.60 (11.12)
59.90 (10.02)
0.3496
58.41 (9.83)
56.88 (8.90)
0.1632
60.63 (10.40)
57.86 (9.28)
0.281
...median [IQR]
64.00 [56.00, 71.00] 60.00 [53.00, 67.00]
0.3779
59.00 [52.00, 63.00] 58.00 [51.00, 63.00]
0.1066
61.13 (10.40)
58.65 (9.28)
0.252
Gender without zero category- United
...Males; n (%)
4,796 (71.3%)
3,152 (77.2%)
-0.1352
6,790 (75.2%)
6,835 (79.9%)
-0.0054
11,586 (73.6%)
9,987 (79.0%)
-0.127
...Females; n (%)
1,925 (28.6%)
933 (22.8%)
0.1330
2,235 (24.8%)
1,722 (20.1%)
-0.0054
4,160 (26.4%)
2,655 (21.0%)
0.127
...Missing; n (%)
1 (0.0%)
0 (0.0%)
#DIV/0!
Region without zero category- United v3 (lumping missing&
...Northeast; n (%)
732 (10.9%)
300 (7.3%)
0.1254
1,683 (18.6%)
1,345 (15.7%)
0.0770
2,415 (15.3%)
1,645 (13.0%)
0.066
...South; n (%)
2,955 (44.0%)
2,035 (49.8%)
-0.1164
3,993 (44.2%)
3,705 (43.3%)
0.0181
6,948 (44.1%)
5,740 (45.4%)
-0.026
...Midwest; n (%)
1,721 (25.6%)
929 (22.7%)
0.0678
2,321 (25.7%)
2,089 (24.4%)
0.0300
4,042 (25.7%)
3,018 (23.9%)
0.042
...West; n (%)
1,314 (19.5%)
821 (20.1%)
-0.0151
970 (10.7%)
1,285 (15.0%)
-0.1288
2,284 (14.5%)
2,106 (16.7%)
-0.061
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)
...Urban; n (%)
6,388 (70.8%)
6,604 (77.2%)
-0.1463
6,388 (70.8%)
6,604 (77.2%)
-0.1463
...Rural; n (%)
710 (7.9%)
207 (2.4%)
0.2508
710 (7.9%)
207 (2.4%)
0.2508
...Unknown/Missing; n (%)
1,927 (21.4%)
1,746 (20.4%)
0.0246
1,927 (21.4%)
1,746 (20.4%)
0.0246
Commercial vs Medicare Advantage- Business Type Code
...COM = COMMERCIAL; n (%)
3,343 (49.7%)
2,633 (64.5%)
-0.3024
3,343 (49.7%)
2,633 (64.5%)
-0.3024
...MCR = MEDICARE; n (%)
3,379 (50.3%)
1,452 (35.5%)
0.3024
3,379 (50.3%)
1,452 (35.5%)
0.3024
Optum
Marketscan
Pooled
Appendix B

...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE (added in 2015); n (%) 0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data Type
...1 - Fee For Service; n (%)
6,570 (72.8%)
6,428 (75.1%)
-0.0524
6,570 (72.8%)
6,428 (75.1%)
-0.0524
...2 - Encounter; n (%)
732 (8.1%)
757 (8.8%)
-0.0252
732 (8.1%)
757 (8.8%)
-0.0252
...3 - Medicare; n (%)
1,510 (16.7%)
1,196 (14.0%)
0.0750
1,510 (16.7%)
1,196 (14.0%)
0.0750
...4 - Medicare Encounter; n (%)
213 (2.4%)
176 (2.1%)
0.0202
213 (2.4%)
176 (2.1%)
0.0202
Lifestyle factors
Obesity; n (%)
1,853 (27.6%)
1,014 (24.8%)
0.0637
1,853 (20.5%)
1,538 (18.0%)
0.0634
3,706 (23.5%)
2,552 (20.2%)
0.080
Overweight; n (%)
480 (7.1%)
194 (4.7%)
0.1020
330 (3.7%)
161 (1.9%)
0.1093
810 (5.1%)
355 (2.8%)
0.118
Smoking; n (%)
3,323 (49.4%)
1,925 (47.1%)
0.0460
2,999 (33.2%)
2,822 (33.0%)
0.0043
6,322 (40.1%)
4,747 (37.5%)
0.053
Alcohol abuse or dependence+Drug abuse or dependence (f377 (5.6%)
168 (4.1%)
0.0699
293 (3.2%)
266 (3.1%)
0.0057
670 (4.3%)
434 (3.4%)
0.047
Diabetes-related conditions
Diabetic retinopathy; n (%)
138 (2.1%)
60 (1.5%)
0.0451
115 (1.3%)
99 (1.2%)
0.0090
253 (1.6%)
159 (1.3%)
0.025
Occurrence of Diabetic Neuropathy v2 Copy; n (%)
463 (6.9%)
185 (4.5%)
0.1037
318 (3.5%)
249 (2.9%)
0.0341
781 (5.0%)
434 (3.4%)
0.080
Occurrence of diabetic nephropathy V3 with ICD10 Copy; n 386 (5.7%)
132 (3.2%)
0.1215
219 (2.4%)
132 (1.5%)
0.0651
605 (3.8%)
264 (2.1%)
0.101
Hypoglycemia v2; n (%)
21 (0.3%)
36 (0.9%)
-0.0778
71 (0.8%)
79 (0.9%)
-0.0109
092 (0.6%)
115 (0.9%)
-0.035
Hyperglycemia; n (%)
527 (7.8%)
318 (7.8%)
0.0000
563 (6.2%)
438 (5.1%)
0.0477
1,090 (6.9%)
756 (6.0%)
0.037
Disorders of fluid electrolyte and acid-base balance; n (%) 968 (14.4%)
461 (11.3%)
0.0927
815 (9.0%)
691 (8.1%)
0.0322
1,783 (11.3%)
1,152 (9.1%)
0.073
Hyperosmolar hyperglycemic nonketotic syndrome (HONK);21 (0.3%)
12 (0.3%)
0.0000
8 (0.1%)
10 (0.1%)
0.0000
029 (0.2%)
022 (0.2%)
0.000
Diabetic Foot; n (%)
57 (0.8%)
27 (0.7%)
0.0116
45 (0.5%)
54 (0.6%)
-0.0135
102 (0.6%)
081 (0.6%)
0.000
Skin infections v2; n (%)
212 (3.2%)
134 (3.3%)
-0.0056
265 (2.9%)
261 (3.1%)
-0.0117
477 (3.0%)
395 (3.1%)
-0.006
Erectile dysfunction; n (%)
198 (2.9%)
141 (3.5%)
-0.0341
244 (2.7%)
198 (2.3%)
0.0256
442 (2.8%)
339 (2.7%)
0.006
Diabetes with unspecified complication; n (%)
231 (3.4%)
84 (2.1%)
0.0796
223 (2.5%)
184 (2.2%)
0.0198
454 (2.9%)
268 (2.1%)
0.051
Diabetes mellitus without mention of complications; n (%) 2,290 (34.1%)
1,403 (34.3%)
-0.0042
2,797 (31.0%)
2,784 (32.5%)
-0.0322
5,087 (32.3%)
4,187 (33.1%)
-0.017
Diabetes with peripheral circulatory disorders+Gangrene+O232 (3.5%)
66 (1.6%)
0.1207
125 (1.4%)
97 (1.1%)
0.0270
357 (2.3%)
163 (1.3%)
0.075
Diabetes with other ophthalmic manifestations+Retinal de 43 (0.6%)
14 (0.3%)
0.0448
80 (0.9%)
90 (1.1%)
-0.0201
123 (0.8%)
104 (0.8%)
0.000
Cardiovascular-related conditions
Hypertension: 1 inpatient or 2 outpatient claims within 3655,346 (79.5%)
3,106 (76.0%)
0.0842
6,673 (73.9%)
5,846 (68.3%)
0.1238
12,019 (76.3%)
8,952 (70.8%)
0.125
Malignant hypertension; n (%)
171 (2.5%)
190 (4.7%)
-0.1183
2,791 (30.9%)
4,225 (49.4%)
-0.3843
2,962 (18.8%)
4,415 (34.9%)
-0.369
Hyperlipidemia v2; n (%)
5,379 (80.0%)
3,348 (82.0%)
-0.0510
6,450 (71.5%)
5,864 (68.5%)
0.0655
11,829 (75.1%)
9,212 (72.9%)
0.050
Acute MI; n (%)
6,184 (92.0%)
3,877 (94.9%)
-0.1174
8,521 (94.4%)
8,293 (96.9%)
-0.1228
14,705 (93.4%)
12,170 (96.3%)
-0.131
ACS/unstable angina; n (%)
2,766 (41.1%)
1,553 (38.0%)
0.0634
3,475 (38.5%)
3,016 (35.2%)
0.0684
6,241 (39.6%)
4,569 (36.1%)
0.072
Old MI; n (%)
952 (14.2%)
510 (12.5%)
0.0500
774 (8.6%)
705 (8.2%)
0.0144
1,726 (11.0%)
1,215 (9.6%)
0.046
Stable angina; n (%)
1,583 (23.5%)
665 (16.3%)
0.1811
1,561 (17.3%)
1,077 (12.6%)
0.1321
3,144 (20.0%)
1,742 (13.8%)
0.166
Coronary atherosclerosis and other forms of chronic ischem6,461 (96.1%)
3,951 (96.7%)
-0.0322
8,365 (92.7%)
7,850 (91.7%)
0.0373
14,826 (94.2%)
11,801 (93.3%)
0.037
Ischemic stroke (w and w/o mention of cerebral infarction)0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
000 (0.0%)
000 (0.0%)
#DIV/0!
TIA; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
000 (0.0%)
000 (0.0%)
#DIV/0!
Late effects of cerebrovascular disease; n (%)
26 (0.4%)
6 (0.1%)
0.0601
9 (0.1%)
9 (0.1%)
0.0000
035 (0.2%)
015 (0.1%)
0.026
Heart failure (CHF); n (%)
1,300 (19.3%)
634 (15.5%)
0.1004
1,206 (13.4%)
1,105 (12.9%)
0.0148
2,506 (15.9%)
1,739 (13.8%)
0.059
Peripheral Vascular Disease (PVD) or PVD Surgery v2; n (%)369 (5.5%)
164 (4.0%)
0.0706
250 (2.8%)
232 (2.7%)
0.0061
619 (3.9%)
396 (3.1%)
0.044
Atrial fibrillation; n (%)
541 (8.0%)
252 (6.2%)
0.0701
454 (5.0%)
355 (4.1%)
0.0432
995 (6.3%)
607 (4.8%)
0.066
Other cardiac dysrhythmia; n (%)
2,369 (35.2%)
1,204 (29.5%)
0.1221
2,553 (28.3%)
2,010 (23.5%)
0.1097
4,922 (31.3%)
3,214 (25.4%)
0.131
Hemorrhagic stroke+Other cerebrovascular disease+Cerebr39 (0.6%)
13 (0.3%)
0.0448
28 (0.3%)
14 (0.2%)
0.0200
067 (0.4%)
027 (0.2%)
0.037
Other atherosclerosis+Cardiac conduction disorders+Other 2,572 (38.3%)
1,384 (33.9%)
0.0917
2,672 (29.6%)
2,323 (27.1%)
0.0555
5,244 (33.3%)
3,707 (29.3%)
0.086
Previous cardiac procedure (CABG or PTCA or Stent) + Histo6,575 (97.8%)
4,012 (98.2%)
-0.0286
8,349 (92.5%)
7,936 (92.7%)
-0.0076
14,924 (94.8%)
11,948 (94.5%)
0.013
Kidney-related conditions
Occurrence of acute renal disease v2; n (%)
533 (7.9%)
227 (5.6%)
0.0918
425 (4.7%)
294 (3.4%)
0.0660
958 (6.1%)
521 (4.1%)
0.091
Occurrence of hypertensive nephropathy; n (%)
543 (8.1%)
212 (5.2%)
0.1166
316 (3.5%)
229 (2.7%)
0.0462
859 (5.5%)
441 (3.5%)
0.097
Occurrence of miscellaneous renal insufficiency v2; n (%)
338 (5.0%)
187 (4.6%)
0.0187
272 (3.0%)
226 (2.6%)
0.0242
610 (3.9%)
413 (3.3%)
0.032
Appendix B

Occurrence of chronic renal insufficiency w/o CKD (for PS) v306 (4.6%)
164 (4.0%)
0.0296
201 (2.2%)
164 (1.9%)
0.0212
507 (3.2%)
328 (2.6%)
0.036
Chronic kidney disease Stage 1-2 (for PS); n (%)
176 (2.6%)
62 (1.5%)
0.0777
78 (0.9%)
65 (0.8%)
0.0109
254 (1.6%)
127 (1.0%)
0.053
CKD stage 3-6 + dialysis (for PS); n (%)
443 (6.6%)
146 (3.6%)
0.1367
256 (2.8%)
168 (2.0%)
0.0523
699 (4.4%)
314 (2.5%)
0.104
Bladder stones+Kidney stones (for PS); n (%)
133 (2.0%)
76 (1.9%)
0.0072
155 (1.7%)
155 (1.8%)
-0.0076
288 (1.8%)
231 (1.8%)
0.000
Urinary tract infections (UTIs); n (%)
322 (4.8%)
151 (3.7%)
0.0545
256 (2.8%)
265 (3.1%)
-0.0177
578 (3.7%)
416 (3.3%)
0.022
Edema; n (%)
230 (3.4%)
110 (2.7%)
0.0407
202 (2.2%)
159 (1.9%)
0.0212
432 (2.7%)
269 (2.1%)
0.039
Other comorbidities
COPD; n (%)
860 (12.8%)
431 (10.6%)
0.0685
643 (7.1%)
560 (6.5%)
0.0238
1,503 (9.5%)
991 (7.8%)
0.061
Asthma; n (%)
438 (6.5%)
253 (6.2%)
0.0123
445 (4.9%)
371 (4.3%)
0.0286
883 (5.6%)
624 (4.9%)
0.031
Obstructive sleep apnea; n (%)
711 (10.6%)
388 (9.5%)
0.0366
818 (9.1%)
674 (7.9%)
0.0430
1,529 (9.7%)
1,062 (8.4%)
0.045
Pneumonia; n (%)
281 (4.2%)
136 (3.3%)
0.0474
244 (2.7%)
212 (2.5%)
0.0126
525 (3.3%)
348 (2.8%)
0.029
Hyperthyroidism + Hypothyroidism + Other disorders of thy 921 (13.7%)
441 (10.8%)
0.0885
882 (9.8%)
723 (8.4%)
0.0487
1,803 (11.4%)
1,164 (9.2%)
0.072
Liver disease; n (%)
4 (0.1%)
5 (0.1%)
0.0000
3 (0.0%)
1 (0.0%)
#DIV/0!
007 (0.0%)
006 (0.0%)
#DIV/0!
Osteoarthritis; n (%)
1,078 (16.0%)
516 (12.6%)
0.0972
916 (10.1%)
716 (8.4%)
0.0587
1,994 (12.7%)
1,232 (9.7%)
0.095
Other arthritis, arthropathies and musculoskeletal pain; n ( 2,166 (32.2%)
1,211 (29.6%)
0.0563
2,538 (28.1%)
2,206 (25.8%)
0.0519
4,704 (29.9%)
3,417 (27.0%)
0.064
Dorsopathies; n (%)
1,508 (22.4%)
880 (21.5%)
0.0217
1,749 (19.4%)
1,486 (17.4%)
0.0516
3,257 (20.7%)
2,366 (18.7%)
0.050
Fractures; n (%)
136 (2.0%)
68 (1.7%)
0.0223
146 (1.6%)
117 (1.4%)
0.0165
282 (1.8%)
185 (1.5%)
0.024
Falls v2; n (%)
127 (1.9%)
45 (1.1%)
0.0659
56 (0.6%)
35 (0.4%)
0.0284
183 (1.2%)
080 (0.6%)
0.064
Osteoporosis; n (%)
197 (2.9%)
80 (2.0%)
0.0582
120 (1.3%)
72 (0.8%)
0.0491
317 (2.0%)
152 (1.2%)
0.064
Depression; n (%)
635 (9.4%)
382 (9.4%)
0.0000
575 (6.4%)
566 (6.6%)
-0.0081
1,210 (7.7%)
948 (7.5%)
0.008
Anxiety; n (%)
875 (13.0%)
465 (11.4%)
0.0489
804 (8.9%)
608 (7.1%)
0.0664
1,679 (10.7%)
1,073 (8.5%)
0.075
Sleep_Disorder; n (%)
255 (3.8%)
315 (7.7%)
-0.1681
477 (5.3%)
702 (8.2%)
-0.1158
732 (4.6%)
1,017 (8.0%)
-0.140
Dementia; n (%)
118 (1.8%)
34 (0.8%)
0.0884
46 (0.5%)
31 (0.4%)
0.0149
164 (1.0%)
065 (0.5%)
0.058
Delirium; n (%)
60 (0.9%)
27 (0.7%)
0.0225
44 (0.5%)
33 (0.4%)
0.0149
104 (0.7%)
060 (0.5%)
0.026
Psychosis; n (%)
37 (0.6%)
19 (0.5%)
0.0135
25 (0.3%)
17 (0.2%)
0.0200
062 (0.4%)
036 (0.3%)
0.017
Use of medications
Use of ACE inhibitors; n (%)
3,343 (49.7%)
2,234 (54.7%)
-0.1002
4,901 (54.3%)
4,985 (58.3%)
-0.0807
8,244 (52.4%)
7,219 (57.1%)
-0.095
Use of ARBs; n (%)
1,464 (21.8%)
735 (18.0%)
0.0953
1,721 (19.1%)
1,420 (16.6%)
0.0653
3,185 (20.2%)
2,155 (17.0%)
0.082
Use of Loop Diuretics - United; n (%)
620 (9.2%)
250 (6.1%)
0.1168
536 (5.9%)
483 (5.6%)
0.0129
1,156 (7.3%)
733 (5.8%)
0.061
Use of other diuretics- United; n (%)
273 (4.1%)
151 (3.7%)
0.0207
348 (3.9%)
318 (3.7%)
0.0105
621 (3.9%)
469 (3.7%)
0.010
Use of nitrates-United; n (%)
2,800 (41.7%)
1,806 (44.2%)
-0.0505
3,934 (43.6%)
3,837 (44.8%)
-0.0242
6,734 (42.8%)
5,643 (44.6%)
-0.036
Use of other hypertension drugs; n (%)
295 (4.4%)
145 (3.5%)
0.0462
292 (3.2%)
293 (3.4%)
-0.0112
587 (3.7%)
438 (3.5%)
0.011
Use of digoxin- United; n (%)
52 (0.8%)
34 (0.8%)
0.0000
40 (0.4%)
49 (0.6%)
-0.0284
092 (0.6%)
083 (0.7%)
-0.012
Use of Anti-arrhythmics; n (%)
144 (2.1%)
71 (1.7%)
0.0293
122 (1.4%)
159 (1.9%)
-0.0393
266 (1.7%)
230 (1.8%)
-0.008
Use of COPD/asthma meds- United; n (%)
844 (12.6%)
485 (11.9%)
0.0214
971 (10.8%)
928 (10.8%)
0.0000
1,815 (11.5%)
1,413 (11.2%)
0.009
Use of statins; n (%)
6,084 (90.5%)
3,736 (91.5%)
-0.0349
8,217 (91.0%)
7,798 (91.1%)
-0.0035
14,301 (90.8%)
11,534 (91.2%)
-0.014
Use of other lipid-lowering drugs; n (%)
442 (6.6%)
340 (8.3%)
-0.0648
695 (7.7%)
801 (9.4%)
-0.0608
1,137 (7.2%)
1,141 (9.0%)
-0.066
Use of antiplatelet agents; n (%)
532 (7.9%)
340 (8.3%)
-0.0147
616 (6.8%)
695 (8.1%)
-0.0495
1,148 (7.3%)
1,035 (8.2%)
-0.034
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixa230 (3.4%)
81 (2.0%)
0.0865
230 (2.5%)
210 (2.5%)
0.0000
460 (2.9%)
291 (2.3%)
0.038
Use of heparin and other low-molecular weight heparins; n27 (0.4%)
11 (0.3%)
0.0169
0 (0.0%)
0 (0.0%)
#DIV/0!
027 (0.2%)
011 (0.1%)
0.026
Use of NSAIDs; n (%)
996 (14.8%)
539 (13.2%)
0.0461
1,386 (15.4%)
1,189 (13.9%)
0.0424
2,382 (15.1%)
1,728 (13.7%)
0.040
Use of oral corticosteroids; n (%)
1,091 (16.2%)
556 (13.6%)
0.0731
1,337 (14.8%)
1,173 (13.7%)
0.0315
2,428 (15.4%)
1,729 (13.7%)
0.048
Use of bisphosphonate (United); n (%)
75 (1.1%)
33 (0.8%)
0.0309
46 (0.5%)
42 (0.5%)
0.0000
121 (0.8%)
075 (0.6%)
0.024
Use of opioids- United; n (%)
1,316 (19.6%)
924 (22.6%)
-0.0736
1,852 (20.5%)
1,859 (21.7%)
-0.0294
3,168 (20.1%)
2,783 (22.0%)
-0.047
Use of antidepressants; n (%)
1,106 (16.5%)
650 (15.9%)
0.0163
1,388 (15.4%)
1,229 (14.4%)
0.0281
2,494 (15.8%)
1,879 (14.9%)
0.025
Use of antipsychotics; n (%)
93 (1.4%)
36 (0.9%)
0.0469
86 (1.0%)
65 (0.8%)
0.0212
179 (1.1%)
101 (0.8%)
0.031
Use of anticonvulsants; n (%)
635 (9.4%)
293 (7.2%)
0.0798
589 (6.5%)
494 (5.8%)
0.0291
1,224 (7.8%)
787 (6.2%)
0.063
Use of Benzos- United; n (%)
608 (9.0%)
383 (9.4%)
-0.0138
881 (9.8%)
790 (9.2%)
0.0205
1,489 (9.5%)
1,173 (9.3%)
0.007
Use of anxiolytics/hypnotics- United; n (%)
285 (4.2%)
226 (5.5%)
-0.0605
443 (4.9%)
467 (5.5%)
-0.0270
728 (4.6%)
693 (5.5%)
-0.041
Use of dementia meds- United; n (%)
44 (0.7%)
19 (0.5%)
0.0259
27 (0.3%)
8 (0.1%)
0.0448
071 (0.5%)
027 (0.2%)
0.051
Appendix B

Use of antiparkinsonian meds- United; n (%)
118 (1.8%)
46 (1.1%)
0.0586
101 (1.1%)
71 (0.8%)
0.0309
219 (1.4%)
117 (0.9%)
0.047
Use of glucose test strips; n (%)
86 (1.3%)
48 (1.2%)
0.0090
116 (1.3%)
113 (1.3%)
0.0000
202 (1.3%)
161 (1.3%)
0.000
Use of thiazide- United; n (%)
537 (8.0%)
288 (7.1%)
0.0341
606 (6.7%)
544 (6.4%)
0.0121
1,143 (7.3%)
832 (6.6%)
0.028
Use of beta blockers; n (%)
5,753 (85.6%)
3,550 (86.9%)
-0.0378
7,873 (87.2%)
7,618 (89.0%)
-0.0556
13,626 (86.5%)
11,168 (88.3%)
-0.054
Use of calcium channel blockers; n (%)
1,357 (20.2%)
706 (17.3%)
0.0744
1,642 (18.2%)
1,370 (16.0%)
0.0585
2,999 (19.0%)
2,076 (16.4%)
0.068
Use of aspirin; n (%)
1,042 (15.5%)
369 (9.0%)
0.1992
1,807 (20.0%)
925 (10.8%)
0.2570
2,849 (18.1%)
1,294 (10.2%)
0.228
Use of Low Intensity Statins; n (%)
1,500 (22.3%)
1,250 (30.6%)
-0.1890
2,143 (23.7%)
2,734 (32.0%)
-0.1860
3,643 (23.1%)
3,984 (31.5%)
-0.189
Use of High Intensity Statins; n (%)
5,326 (79.2%)
2,878 (70.5%)
0.2015
7,021 (77.8%)
5,772 (67.5%)
0.2326
12,347 (78.4%)
8,650 (68.4%)
0.228
Use of Sympatomimetic agents; n (%)
66 (1.0%)
45 (1.1%)
-0.0098
121 (1.3%)
85 (1.0%)
0.0281
187 (1.2%)
130 (1.0%)
0.019
Use of CNS stimulants; n (%)
27 (0.4%)
13 (0.3%)
0.0169
44 (0.5%)
54 (0.6%)
-0.0135
071 (0.5%)
067 (0.5%)
0.000
All antidiabetic medications except Insulin; n (%)
1,603 (23.8%)
915 (22.4%)
0.0332
2,040 (22.6%)
1,948 (22.8%)
-0.0048
3,643 (23.1%)
2,863 (22.6%)
0.012
DM Medications - Insulin Copy; n (%)
616 (9.2%)
352 (8.6%)
0.0211
817 (9.1%)
765 (8.9%)
0.0070
1,433 (9.1%)
1,117 (8.8%)
0.011
Use of estrogens, progestins, androgens; n (%)
195 (2.9%)
153 (3.7%)
-0.0448
381 (4.2%)
381 (4.5%)
-0.0147
576 (3.7%)
534 (4.2%)
-0.026
Use of Angiogenesis inhibitors; n (%)
4 (0.1%)
0 (0.0%)
0.0447
1 (0.0%)
0 (0.0%)
#DIV/0!
005 (0.0%)
000 (0.0%)
#DIV/0!
Use of Oral Immunosuppressants; n (%)
7 (0.1%)
4 (0.1%)
0.0000
18 (0.2%)
15 (0.2%)
0.0000
025 (0.2%)
019 (0.2%)
0.000
Use of fondaparinux or Bivalirudin; n (%)
0 (0.0%)
2 (0.0%)
#DIV/0!
0 (0.0%)
2 (0.0%)
#DIV/0!
000 (0.0%)
004 (0.0%)
#DIV/0!
Use of other direct thrombin inhibitors (lepirudin, desirudin0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
000 (0.0%)
000 (0.0%)
#DIV/0!
Use of CYP inhibitors; n (%)
1,063 (15.8%)
645 (15.8%)
0.0000
1,373 (15.2%)
1,295 (15.1%)
0.0028
2,436 (15.5%)
1,940 (15.3%)
0.006
Use of CYP inducers; n (%)
19 (0.3%)
14 (0.3%)
0.0000
27 (0.3%)
33 (0.4%)
-0.0169
046 (0.3%)
047 (0.4%)
-0.017
Burden of disease/Healthcare utilization
Combined comorbidity score, 180 days Copy
...mean (sd)
1.51 (1.96)
0.93 (1.74)
0.3130
0.74 (1.54)
0.50 (1.43)
0.1615
1.07 (1.73)
0.64 (1.54)
0.263
...median [IQR]
1.00 [0.00, 3.00]
1.00 [0.00, 2.00]
0.0000
0.00 [0.00, 2.00]
0.00 [-1.00, 1.00]
0.0000
0.43 (1.73)
0.32 (1.54)
0.067
Frailty Score (mean): Empirical Version 365 days, v2
...mean (sd)
0.18 (0.04)
0.17 (0.04)
0.2500
0.17 (0.03)
0.17 (0.03)
0.0000
0.17 (0.03)
0.17 (0.03)
0.000
...median [IQR]
0.17 [0.15, 0.20]
0.17 [0.15, 0.19]
0.0000
0.16 [0.15, 0.19]
0.16 [0.14, 0.18]
0.0000
0.16 (0.03)
0.16 (0.03)
0.000
Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level 
...mean (sd)
11.01 (9.01)
6.41 (8.19)
0.5343
7.66 (8.06)
4.42 (7.09)
0.4268
9.09 (8.48)
5.06 (7.46)
0.505
...median [IQR]
10.00 [4.00, 17.00]
3.00 [0.00, 11.00]
0.8130
6.00 [0.00, 14.00]
0.00 [0.00, 9.00]
0.7905
7.71 (8.48)
0.97 (7.46)
0.844
HAS-BLED Score (ICD-9 and ICD-10), 180 days
...mean (sd)
3.50 (0.58)
3.35 (0.56)
0.2631
3.18 (0.48)
3.14 (0.44)
0.0869
3.32 (0.53)
3.21 (0.48)
0.218
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.0000
3.00 [3.00, 3.00]
3.00 [3.00, 3.00]
0.0000
3.00 (0.53)
3.00 (0.48)
0.000
number of different/distinct medication prescriptions
...mean (sd)
8.94 (4.49)
8.53 (4.32)
0.0931
8.71 (4.31)
8.50 (4.18)
0.0495
8.81 (4.39)
8.51 (4.23)
0.070
...median [IQR]
8.00 [6.00, 11.00]
8.00 [5.00, 11.00]
0.0000
8.00 [6.00, 11.00]
8.00 [5.00, 11.00]
0.0000
8.00 (4.39)
8.00 (4.23)
0.000
Any hospitalization within prior 30 days; n (%)
6,722 (100.0%)
4,085 (100.0%)
#DIV/0!
9,025 (100.0%)
8,557 (100.0%)
#DIV/0!
15,747 (100.0%)
12,642 (100.0%)
#DIV/0!
Number of Hospitalizations
...mean (sd)
1.08 (0.30)
1.08 (0.32)
0.0000
1.06 (0.26)
1.08 (0.29)
-0.0726
1.07 (0.28)
1.08 (0.30)
-0.034
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.0000
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.0000
1.00 (0.28)
1.00 (0.30)
0.000
Number of hospital days
...mean (sd)
3.60 (1.94)
3.61 (1.94)
-0.0052
3.42 (1.84)
3.60 (1.80)
-0.0989
3.50 (1.88)
3.60 (1.85)
-0.054
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.0000
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.0000
3.00 (1.88)
3.00 (1.85)
0.000
Number of Emergency Department (ED) visits v3
...mean (sd)
1.07 (1.30)
1.06 (1.32)
0.0076
3.52 (5.63)
3.31 (6.05)
0.0359
2.47 (4.35)
2.58 (5.03)
-0.023
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.0000
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.0000
1.57 (4.35)
1.68 (5.03)
-0.023
Number of Office visits
...mean (sd)
3.12 (3.16)
2.92 (3.33)
0.0616
2.77 (2.94)
2.67 (2.93)
0.0341
2.92 (3.04)
2.75 (3.06)
0.056
...median [IQR]
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 (3.04)
2.00 (3.06)
0.000
Number of internal medicine/family medicine visits
...mean (sd)
7.11 (10.84)
5.72 (9.60)
0.1358
3.93 (5.98)
3.75 (6.60)
0.0286
5.29 (8.41)
4.39 (7.70)
0.112
...median [IQR]
4.00 [1.00, 9.00]
3.00 [0.00, 7.00]
0.0977
2.00 [0.00, 5.00]
2.00 [0.00, 5.00]
0.0000
2.85 (8.41)
2.32 (7.70)
0.066
Appendix B

Number of Cardiologist visits
...mean (sd)
8.41 (5.38)
8.07 (4.88)
0.0662
1.06 (2.17)
0.97 (2.18)
0.0414
4.20 (3.88)
3.26 (3.30)
0.261
...median [IQR]
8.00 [5.00, 11.00]
7.00 [5.00, 10.00]
0.1947
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.0000
3.41 (3.88)
2.26 (3.30)
0.319
Number electrocardiograms received v2
...mean (sd)
3.28 (2.45)
3.32 (2.52)
-0.0161
0.98 (1.33)
1.05 (1.40)
-0.0513
1.96 (1.89)
1.78 (1.84)
0.097
...median [IQR]
3.00 [2.00, 4.00]
3.00 [2.00, 5.00]
0.0000
1.00 [0.00, 1.00]
1.00 [0.00, 2.00]
0.0000
1.85 (1.89)
1.65 (1.84)
0.107
Number of BNP tests
...mean (sd)
0.10 (0.37)
0.10 (0.37)
0.0000
0.12 (0.38)
0.13 (0.39)
-0.0260
0.11 (0.38)
0.12 (0.38)
-0.026
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.38)
0.00 (0.38)
0.000
Number of Cardiac biomarkers tests (tropnin, CK-MBs, Myo
...mean (sd)
0.68 (1.66)
0.76 (1.77)
-0.0466
0.69 (1.61)
0.83 (1.79)
-0.0822
0.69 (1.63)
0.81 (1.78)
-0.070
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.0000
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.0000
0.00 (1.63)
0.00 (1.78)
0.000
Number of Ambulatory Blood pressure monitoring tests
...mean (sd)
0.00 (0.02)
0.00 (0.02)
0.0000
0.00 (0.04)
0.00 (0.03)
0.0000
0.00 (0.03)
0.00 (0.03)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.03)
0.00 (0.03)
0.000
N of days on antihypertensive medications during baseline
...mean (sd)
81.19 (79.68)
71.98 (77.47)
0.1172
74.18 (78.62)
68.85 (77.22)
0.0684
77.17 (79.07)
69.86 (77.30)
0.093
...median [IQR]
62.50 [1.00, 172.00] 21.00 [1.00, 164.00]
0.5281
29.00 [1.00, 167.00] 8.00 [1.00, 162.00]
0.2695
43.30 (79.07)
12.20 (77.30)
0.398
N of days in database anytime prior
...mean (sd)
1,685.49 (1,370.91) 1,619.30 (1,246.27)
0.0505
2,118.05 (1,473.24) 1,786.28 (1,260.85)
0.2420
1933.40 (1430.45)
1732.32 (1256.16)
0.149
...median [IQR]
1,246.00 [606.00, 2,41,242.00 [605.00, 2,4
0.0031
1,804.00 [830.00, 3,21,443.00 [726.00, 2,7
0.2633
1565.80 (1430.45)
1378.05 (1256.16)
0.139
Mean Copay for per prescription cost (charges in U.S. $) (18
...mean (sd)
21.80 (31.56)
25.04 (28.00)
-0.1086
15.43 (20.81)
18.99 (25.39)
-0.1534
18.15 (25.95)
20.94 (26.26)
-0.107
...median [IQR]
13.33 [5.00, 27.78]
17.11 [7.40, 33.33]
-0.1267
10.00 [1.98, 21.01]
12.44 [4.50, 25.29]
-0.1051
11.42 (25.95)
13.95 (26.26)
-0.097
...Missing; n (%)
879 (13.1%)
638 (15.6%)
-0.0714
1,391 (15.4%)
1,411 (16.5%)
-0.0300
2,270 (14.4%)
2,049 (16.2%)
-0.050
Duration of index hospitalization (i.e. anchor hospitalizatio
...mean (sd)
1.00 (0.00)
1.00 (0.00)
#DIV/0!
1.00 (0.00)
1.00 (0.00)
#DIV/0!
1.00 (0.00)
1.00 (0.00)
#DIV/0!
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
#DIV/0!
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
#DIV/0!
1.00 (0.00)
1.00 (0.00)
#DIV/0!
N of Generic name drugs
...mean (sd)
13.03 (11.49)
11.70 (10.59)
0.1204
11.38 (9.78)
10.30 (8.90)
0.1155
12.08 (10.54)
10.75 (9.48)
0.133
...median [IQR]
10.00 [5.00, 17.00]
8.00 [4.00, 16.00]
0.1810
9.00 [5.00, 15.00]
8.00 [4.00, 14.00]
0.1069
9.43 (10.54)
8.00 (9.48)
0.143
N of Brand name drugs
...mean (sd)
3.08 (3.59)
3.51 (4.09)
-0.1117
3.42 (3.62)
3.99 (4.24)
-0.1446
3.27 (3.61)
3.83 (4.19)
-0.143
...median [IQR]
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 [1.00, 4.00]
2.00 [1.00, 5.00]
0.0000
2.00 (3.61)
2.00 (4.19)
0.000
Number of D-dimer tests
...mean (sd)
0.06 (0.25)
0.06 (0.25)
0.0000
0.07 (0.28)
0.07 (0.29)
0.0000
0.07 (0.27)
0.07 (0.28)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.27)
0.00 (0.28)
0.000
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.05 (0.30)
0.04 (0.33)
0.0317
0.04 (0.27)
0.04 (0.26)
0.0000
0.04 (0.28)
0.04 (0.28)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.28)
0.00 (0.28)
0.000
Number of PT or aPTTt tests
...mean (sd)
0.39 (1.09)
0.36 (0.99)
0.0288
0.37 (0.92)
0.44 (1.04)
-0.0713
0.38 (1.00)
0.41 (1.02)
-0.030
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 1.00]
0.0000
0.00 (1.00)
0.00 (1.02)
0.000
Number of Bleeding time tests
...mean (sd)
0.00 (0.02)
0.00 (0.00)
0.0000
0.00 (0.01)
0.00 (0.00)
0.0000
0.00 (0.02)
0.00 (0.00)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.02)
0.00 (0.00)
0.000
Occurrence of creatinine tests  ordered (for PS); n (%)
227 (3.4%)
107 (2.6%)
0.0469
228 (2.5%)
265 (3.1%)
-0.0364
455 (2.9%)
372 (2.9%)
0.000
Cardiovascular stress test; n (%)
15 (0.2%)
6 (0.1%)
0.0258
15 (0.2%)
15 (0.2%)
0.0000
030 (0.2%)
021 (0.2%)
0.000
Echocardiogram; n (%)
5,099 (75.9%)
2,718 (66.5%)
0.2087
6,478 (71.8%)
5,447 (63.7%)
0.1739
11,577 (73.5%)
8,165 (64.6%)
0.193
Colonoscopy; n (%)
222 (3.3%)
152 (3.7%)
-0.0218
329 (3.6%)
294 (3.4%)
0.0109
551 (3.5%)
446 (3.5%)
0.000
Fecal occult blood (FOB) test; n (%)
163 (2.4%)
115 (2.8%)
-0.0251
224 (2.5%)
226 (2.6%)
-0.0063
387 (2.5%)
341 (2.7%)
-0.013
Appendix B

Flu vaccine; n (%)
978 (14.5%)
523 (12.8%)
0.0495
768 (8.5%)
687 (8.0%)
0.0182
1,746 (11.1%)
1,210 (9.6%)
0.049
Mammogram; n (%)
396 (5.9%)
170 (4.2%)
0.0777
369 (4.1%)
301 (3.5%)
0.0314
765 (4.9%)
471 (3.7%)
0.059
Pap smear; n (%)
132 (2.0%)
85 (2.1%)
-0.0071
174 (1.9%)
182 (2.1%)
-0.0143
306 (1.9%)
267 (2.1%)
-0.014
Pneumonia vaccine; n (%)
1,315 (19.6%)
496 (12.1%)
0.2065
754 (8.4%)
461 (5.4%)
0.1186
2,069 (13.1%)
957 (7.6%)
0.181
PSA test or Prostate exam for DRE; n (%)
1,018 (15.1%)
646 (15.8%)
-0.0194
1,125 (12.5%)
1,167 (13.6%)
-0.0327
2,143 (13.6%)
1,813 (14.3%)
-0.020
Bone mineral density; n (%)
110 (1.6%)
60 (1.5%)
0.0081
79 (0.9%)
47 (0.5%)
0.0480
189 (1.2%)
107 (0.8%)
0.040
Drug eluting stent; n (%)
998 (14.8%)
1,987 (48.6%)
-0.7796
2,503 (27.7%)
3,877 (45.3%)
-0.3718
3,501 (22.2%)
5,864 (46.4%)
-0.527
Bare metal stent; n (%)
5,844 (86.9%)
2,853 (69.8%)
0.4244
7,737 (85.7%)
4,842 (56.6%)
0.6782
13,581 (86.2%)
7,695 (60.9%)
0.599
Appendix B

Ticagrelor
Prasugrel
St. Diff
Ticagrelor
Prasugrel
St. Diff
Ticagrelor
Prasugrel
St. Diff
Number of patients
2,498
2,498
4,802
4,802
 7,300 
 7,300 
Quarter/Year of Cohort Entry Date
...Q3 2011; n (%)
1 (0.0%)
0 (0.0%)
#DIV/0!
2 (0.0%)
2 (0.0%)
#DIV/0!
003 (0.0%)
002 (0.0%)
#DIV/0!
...Q4 2011; n (%)
2 (0.1%)
2 (0.1%)
0.0000
19 (0.4%)
20 (0.4%)
0.0000
021 (0.3%)
022 (0.3%)
0.000
...Q1 2012; n (%)
11 (0.4%)
16 (0.6%)
-0.0284
51 (1.1%)
42 (0.9%)
0.0201
062 (0.8%)
058 (0.8%)
0.000
...Q2 2012; n (%)
30 (1.2%)
23 (0.9%)
0.0294
104 (2.2%)
98 (2.0%)
0.0139
134 (1.8%)
121 (1.7%)
0.008
...Q3 2012; n (%)
44 (1.8%)
51 (2.0%)
-0.0146
142 (3.0%)
156 (3.2%)
-0.0115
186 (2.5%)
207 (2.8%)
-0.019
...Q4 2012; n (%)
42 (1.7%)
54 (2.2%)
-0.0362
177 (3.7%)
189 (3.9%)
-0.0105
219 (3.0%)
243 (3.3%)
-0.017
...Q1 2013; n (%)
78 (3.1%)
67 (2.7%)
0.0238
171 (3.6%)
176 (3.7%)
-0.0053
249 (3.4%)
243 (3.3%)
0.006
...Q2 2013; n (%)
89 (3.6%)
78 (3.1%)
0.0278
188 (3.9%)
190 (4.0%)
-0.0051
277 (3.8%)
268 (3.7%)
0.005
...Q3 2013; n (%)
70 (2.8%)
71 (2.8%)
0.0000
243 (5.1%)
253 (5.3%)
-0.0090
313 (4.3%)
324 (4.4%)
-0.005
...Q4 2013; n (%)
75 (3.0%)
73 (2.9%)
0.0059
249 (5.2%)
235 (4.9%)
0.0137
324 (4.4%)
308 (4.2%)
0.010
...Q1 2014; n (%)
77 (3.1%)
74 (3.0%)
0.0058
224 (4.7%)
223 (4.6%)
0.0047
301 (4.1%)
297 (4.1%)
0.000
...Q2 2014; n (%)
79 (3.2%)
70 (2.8%)
0.0235
258 (5.4%)
265 (5.5%)
-0.0044
337 (4.6%)
335 (4.6%)
0.000
...Q3 2014; n (%)
89 (3.6%)
76 (3.0%)
0.0336
278 (5.8%)
291 (6.1%)
-0.0127
367 (5.0%)
367 (5.0%)
0.000
...Q4 2014; n (%)
90 (3.6%)
78 (3.1%)
0.0278
302 (6.3%)
285 (5.9%)
0.0167
392 (5.4%)
363 (5.0%)
0.018
...Q1 2015; n (%)
67 (2.7%)
71 (2.8%)
-0.0061
186 (3.9%)
188 (3.9%)
0.0000
253 (3.5%)
259 (3.5%)
0.000
...Q2 2015; n (%)
63 (2.5%)
62 (2.5%)
0.0000
158 (3.3%)
166 (3.5%)
-0.0110
221 (3.0%)
228 (3.1%)
-0.006
...Q3 2015; n (%)
78 (3.1%)
77 (3.1%)
0.0000
205 (4.3%)
191 (4.0%)
0.0150
283 (3.9%)
268 (3.7%)
0.010
...Q4 2015; n (%)
100 (4.0%)
90 (3.6%)
0.0209
249 (5.2%)
234 (4.9%)
0.0137
349 (4.8%)
324 (4.4%)
0.019
...Q1 2016; n (%)
84 (3.4%)
91 (3.6%)
-0.0109
263 (5.5%)
244 (5.1%)
0.0179
347 (4.8%)
335 (4.6%)
0.009
...Q2 2016; n (%)
97 (3.9%)
102 (4.1%)
-0.0102
236 (4.9%)
230 (4.8%)
0.0047
333 (4.6%)
332 (4.5%)
0.005
...Q3 2016; n (%)
104 (4.2%)
112 (4.5%)
-0.0147
249 (5.2%)
232 (4.8%)
0.0184
353 (4.8%)
344 (4.7%)
0.005
...Q4 2016; n (%)
129 (5.2%)
123 (4.9%)
0.0137
216 (4.5%)
225 (4.7%)
-0.0095
345 (4.7%)
348 (4.8%)
-0.005
...Q1 2017; n (%)
100 (4.0%)
113 (4.5%)
-0.0248
141 (2.9%)
158 (3.3%)
-0.0231
241 (3.3%)
271 (3.7%)
-0.022
...Q2 2017; n (%)
110 (4.4%)
122 (4.9%)
-0.0237
159 (3.3%)
162 (3.4%)
-0.0056
269 (3.7%)
284 (3.9%)
-0.010
...Q3 2017; n (%)
119 (4.8%)
125 (5.0%)
-0.0093
173 (3.6%)
192 (4.0%)
-0.0209
292 (4.0%)
317 (4.3%)
-0.015
...Q4 2017; n (%)
107 (4.3%)
122 (4.9%)
-0.0286
158 (3.3%)
154 (3.2%)
0.0056
265 (3.6%)
276 (3.8%)
-0.011
...Q1 2018; n (%)
92 (3.7%)
96 (3.8%)
-0.0053
1 (0.0%)
1 (0.0%)
#DIV/0!
093 (1.3%)
097 (1.3%)
0.000
Demographics
Age
...mean (sd)
61.84 (11.27)
61.48 (10.03)
0.0337
57.39 (9.86)
57.47 (8.66)
-0.0086
58.91 (10.36)
58.84 (9.15)
0.007
...median [IQR]
62.00 [54.00, 70.00] 62.00 [55.00, 69.00]
0.0000
58.00 [51.00, 63.00] 58.00 [52.00, 63.00]
0.0000
59.37 (10.36)
59.37 (9.15)
0.000
Gender without zero category- United
...Males; n (%)
1,877 (75.1%)
1,880 (75.3%)
-0.0046
3,759 (78.3%)
3,743 (77.9%)
0.0005
5,636 (77.2%)
5,623 (77.0%)
0.005
...Females; n (%)
621 (24.9%)
618 (24.7%)
0.0046
1,043 (21.7%)
1,059 (22.1%)
0.0005
1,664 (22.8%)
1,677 (23.0%)
-0.005
Region without zero category- United v3 (lumping missing&
...Northeast; n (%)
234 (9.4%)
215 (8.6%)
0.0280
784 (16.3%)
779 (16.2%)
0.0027
1,018 (13.9%)
994 (13.6%)
0.009
...South; n (%)
1,185 (47.4%)
1,187 (47.5%)
-0.0020
2,159 (45.0%)
2,186 (45.5%)
-0.0100
3,344 (45.8%)
3,373 (46.2%)
-0.008
...Midwest; n (%)
576 (23.1%)
584 (23.4%)
-0.0071
1,178 (24.5%)
1,165 (24.3%)
0.0047
1,754 (24.0%)
1,749 (24.0%)
0.000
...West; n (%)
503 (20.1%)
512 (20.5%)
-0.0099
629 (13.1%)
614 (12.8%)
0.0089
1,132 (15.5%)
1,126 (15.4%)
0.003
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)
...Urban; n (%)
3,606 (75.1%)
3,607 (75.1%)
0.0000
3,606 (75.1%)
3,607 (75.1%)
0.0000
...Rural; n (%)
204 (4.2%)
207 (4.3%)
-0.0050
204 (4.2%)
207 (4.3%)
-0.0050
...Unknown/Missing; n (%)
992 (20.7%)
988 (20.6%)
0.0025
992 (20.7%)
988 (20.6%)
0.0025
Commercial vs Medicare Advantage- Business Type Code
...COM = COMMERCIAL; n (%)
1,370 (54.8%)
1,414 (56.6%)
-0.0362
1,370 (54.8%)
1,414 (56.6%)
-0.0362
...MCR = MEDICARE; n (%)
1,128 (45.2%)
1,084 (43.4%)
0.0362
1,128 (45.2%)
1,084 (43.4%)
0.0362
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Optum
Marketscan
Pooled
Appendix B

...NONE = NO BUSINESS LINE CODE (added in 2015); n (%) 0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data Type
...1 - Fee For Service; n (%)
3,556 (74.1%)
3,566 (74.3%)
-0.0046
3,556 (74.1%)
3,566 (74.3%)
-0.0046
...2 - Encounter; n (%)
419 (8.7%)
418 (8.7%)
0.0000
419 (8.7%)
418 (8.7%)
0.0000
...3 - Medicare; n (%)
725 (15.1%)
714 (14.9%)
0.0056
725 (15.1%)
714 (14.9%)
0.0056
...4 - Medicare Encounter; n (%)
102 (2.1%)
104 (2.2%)
-0.0069
102 (2.1%)
104 (2.2%)
-0.0069
Lifestyle factors
Obesity; n (%)
647 (25.9%)
658 (26.3%)
-0.0091
966 (20.1%)
937 (19.5%)
0.0151
1,613 (22.1%)
1,595 (21.8%)
0.007
Overweight; n (%)
134 (5.4%)
155 (6.2%)
-0.0342
111 (2.3%)
119 (2.5%)
-0.0131
245 (3.4%)
274 (3.8%)
-0.021
Smoking; n (%)
1,220 (48.8%)
1,220 (48.8%)
0.0000
1,586 (33.0%)
1,579 (32.9%)
0.0021
2,806 (38.4%)
2,799 (38.3%)
0.002
Alcohol abuse or dependence+Drug abuse or dependence (f133 (5.3%)
120 (4.8%)
0.0228
157 (3.3%)
150 (3.1%)
0.0114
290 (4.0%)
270 (3.7%)
0.016
Diabetes-related conditions
Diabetic retinopathy; n (%)
39 (1.6%)
38 (1.5%)
0.0081
61 (1.3%)
56 (1.2%)
0.0090
100 (1.4%)
094 (1.3%)
0.009
Occurrence of Diabetic Neuropathy v2 Copy; n (%)
138 (5.5%)
141 (5.6%)
-0.0044
158 (3.3%)
159 (3.3%)
0.0000
296 (4.1%)
300 (4.1%)
0.000
Occurrence of diabetic nephropathy V3 with ICD10 Copy; n 97 (3.9%)
112 (4.5%)
-0.0299
79 (1.6%)
86 (1.8%)
-0.0155
176 (2.4%)
198 (2.7%)
-0.019
Hypoglycemia v2; n (%)
18 (0.7%)
15 (0.6%)
0.0124
50 (1.0%)
49 (1.0%)
0.0000
068 (0.9%)
064 (0.9%)
0.000
Hyperglycemia; n (%)
205 (8.2%)
199 (8.0%)
0.0073
290 (6.0%)
294 (6.1%)
-0.0042
495 (6.8%)
493 (6.8%)
0.000
Disorders of fluid electrolyte and acid-base balance; n (%) 302 (12.1%)
310 (12.4%)
-0.0092
432 (9.0%)
416 (8.7%)
0.0106
734 (10.1%)
726 (9.9%)
0.007
Hyperosmolar hyperglycemic nonketotic syndrome (HONK);9 (0.4%)
9 (0.4%)
0.0000
3 (0.1%)
6 (0.1%)
0.0000
012 (0.2%)
015 (0.2%)
0.000
Diabetic Foot; n (%)
24 (1.0%)
20 (0.8%)
0.0212
29 (0.6%)
30 (0.6%)
0.0000
053 (0.7%)
050 (0.7%)
0.000
Skin infections v2; n (%)
83 (3.3%)
83 (3.3%)
0.0000
157 (3.3%)
151 (3.1%)
0.0114
240 (3.3%)
234 (3.2%)
0.006
Erectile dysfunction; n (%)
80 (3.2%)
82 (3.3%)
-0.0056
138 (2.9%)
129 (2.7%)
0.0121
218 (3.0%)
211 (2.9%)
0.006
Diabetes with unspecified complication; n (%)
60 (2.4%)
65 (2.6%)
-0.0128
117 (2.4%)
118 (2.5%)
-0.0065
177 (2.4%)
183 (2.5%)
-0.006
Diabetes mellitus without mention of complications; n (%) 821 (32.9%)
854 (34.2%)
-0.0275
1,551 (32.3%)
1,561 (32.5%)
-0.0043
2,372 (32.5%)
2,415 (33.1%)
-0.013
Diabetes with peripheral circulatory disorders+Gangrene+O44 (1.8%)
54 (2.2%)
-0.0286
55 (1.1%)
58 (1.2%)
-0.0094
099 (1.4%)
112 (1.5%)
-0.008
Diabetes with other ophthalmic manifestations+Retinal de 10 (0.4%)
11 (0.4%)
0.0000
48 (1.0%)
45 (0.9%)
0.0103
058 (0.8%)
056 (0.8%)
0.000
Cardiovascular-related conditions
Hypertension: 1 inpatient or 2 outpatient claims within 3651,929 (77.2%)
1,929 (77.2%)
0.0000
3,455 (71.9%)
3,453 (71.9%)
0.0000
5,384 (73.8%)
5,382 (73.7%)
0.002
Malignant hypertension; n (%)
109 (4.4%)
104 (4.2%)
0.0099
2,019 (42.0%)
2,011 (41.9%)
0.0020
2,128 (29.2%)
2,115 (29.0%)
0.004
Hyperlipidemia v2; n (%)
2,030 (81.3%)
2,020 (80.9%)
0.0102
3,419 (71.2%)
3,412 (71.1%)
0.0022
5,449 (74.6%)
5,432 (74.4%)
0.005
Acute MI; n (%)
2,312 (92.6%)
2,315 (92.7%)
-0.0038
4,566 (95.1%)
4,566 (95.1%)
0.0000
6,878 (94.2%)
6,881 (94.3%)
-0.004
ACS/unstable angina; n (%)
1,044 (41.8%)
1,017 (40.7%)
0.0223
1,795 (37.4%)
1,824 (38.0%)
-0.0124
2,839 (38.9%)
2,841 (38.9%)
0.000
Old MI; n (%)
351 (14.1%)
343 (13.7%)
0.0116
408 (8.5%)
423 (8.8%)
-0.0107
759 (10.4%)
766 (10.5%)
-0.003
Stable angina; n (%)
509 (20.4%)
506 (20.3%)
0.0025
716 (14.9%)
717 (14.9%)
0.0000
1,225 (16.8%)
1,223 (16.8%)
0.000
Coronary atherosclerosis and other forms of chronic ischem2,408 (96.4%)
2,407 (96.4%)
0.0000
4,455 (92.8%)
4,454 (92.8%)
0.0000
6,863 (94.0%)
6,861 (94.0%)
0.000
Ischemic stroke (w and w/o mention of cerebral infarction)0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
000 (0.0%)
000 (0.0%)
#DIV/0!
TIA; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
000 (0.0%)
000 (0.0%)
#DIV/0!
Late effects of cerebrovascular disease; n (%)
5 (0.2%)
5 (0.2%)
0.0000
2 (0.0%)
3 (0.1%)
-0.0447
007 (0.1%)
008 (0.1%)
0.000
Heart failure (CHF); n (%)
433 (17.3%)
428 (17.1%)
0.0053
642 (13.4%)
641 (13.3%)
0.0029
1,075 (14.7%)
1,069 (14.6%)
0.003
Peripheral Vascular Disease (PVD) or PVD Surgery v2; n (%)108 (4.3%)
117 (4.7%)
-0.0193
130 (2.7%)
135 (2.8%)
-0.0061
238 (3.3%)
252 (3.5%)
-0.011
Atrial fibrillation; n (%)
180 (7.2%)
170 (6.8%)
0.0157
194 (4.0%)
210 (4.4%)
-0.0199
374 (5.1%)
380 (5.2%)
-0.005
Other cardiac dysrhythmia; n (%)
799 (32.0%)
772 (30.9%)
0.0237
1,200 (25.0%)
1,244 (25.9%)
-0.0207
1,999 (27.4%)
2,016 (27.6%)
-0.004
Hemorrhagic stroke+Other cerebrovascular disease+Cerebr12 (0.5%)
12 (0.5%)
0.0000
13 (0.3%)
11 (0.2%)
0.0200
025 (0.3%)
023 (0.3%)
0.000
Other atherosclerosis+Cardiac conduction disorders+Other 883 (35.3%)
880 (35.2%)
0.0021
1,345 (28.0%)
1,355 (28.2%)
-0.0044
2,228 (30.5%)
2,235 (30.6%)
-0.002
Previous cardiac procedure (CABG or PTCA or Stent) + Histo2,455 (98.3%)
2,459 (98.4%)
-0.0079
4,491 (93.5%)
4,482 (93.3%)
0.0081
6,946 (95.2%)
6,941 (95.1%)
0.005
Kidney-related conditions
Occurrence of acute renal disease v2; n (%)
169 (6.8%)
179 (7.2%)
-0.0157
192 (4.0%)
182 (3.8%)
0.0103
361 (4.9%)
361 (4.9%)
0.000
Occurrence of hypertensive nephropathy; n (%)
160 (6.4%)
166 (6.6%)
-0.0081
133 (2.8%)
147 (3.1%)
-0.0177
293 (4.0%)
313 (4.3%)
-0.015
Occurrence of miscellaneous renal insufficiency v2; n (%)
131 (5.2%)
127 (5.1%)
0.0045
126 (2.6%)
137 (2.9%)
-0.0183
257 (3.5%)
264 (3.6%)
-0.005
Occurrence of chronic renal insufficiency w/o CKD (for PS) v115 (4.6%)
114 (4.6%)
0.0000
91 (1.9%)
101 (2.1%)
-0.0143
206 (2.8%)
215 (2.9%)
-0.006
Appendix B

Chronic kidney disease Stage 1-2 (for PS); n (%)
50 (2.0%)
52 (2.1%)
-0.0071
43 (0.9%)
47 (1.0%)
-0.0103
093 (1.3%)
099 (1.4%)
-0.009
CKD stage 3-6 + dialysis (for PS); n (%)
133 (5.3%)
123 (4.9%)
0.0182
108 (2.2%)
110 (2.3%)
-0.0067
241 (3.3%)
233 (3.2%)
0.006
Bladder stones+Kidney stones (for PS); n (%)
54 (2.2%)
52 (2.1%)
0.0069
92 (1.9%)
87 (1.8%)
0.0074
146 (2.0%)
139 (1.9%)
0.007
Urinary tract infections (UTIs); n (%)
104 (4.2%)
115 (4.6%)
-0.0195
150 (3.1%)
146 (3.0%)
0.0058
254 (3.5%)
261 (3.6%)
-0.005
Edema; n (%)
67 (2.7%)
78 (3.1%)
-0.0238
97 (2.0%)
98 (2.0%)
0.0000
164 (2.2%)
176 (2.4%)
-0.013
Other comorbidities
COPD; n (%)
310 (12.4%)
306 (12.2%)
0.0061
324 (6.7%)
336 (7.0%)
-0.0119
634 (8.7%)
642 (8.8%)
-0.004
Asthma; n (%)
146 (5.8%)
162 (6.5%)
-0.0291
220 (4.6%)
215 (4.5%)
0.0048
366 (5.0%)
377 (5.2%)
-0.009
Obstructive sleep apnea; n (%)
259 (10.4%)
259 (10.4%)
0.0000
392 (8.2%)
412 (8.6%)
-0.0144
651 (8.9%)
671 (9.2%)
-0.010
Pneumonia; n (%)
87 (3.5%)
87 (3.5%)
0.0000
137 (2.9%)
127 (2.6%)
0.0183
224 (3.1%)
214 (2.9%)
0.012
Hyperthyroidism + Hypothyroidism + Other disorders of thy 278 (11.1%)
304 (12.2%)
-0.0343
429 (8.9%)
452 (9.4%)
-0.0173
707 (9.7%)
756 (10.4%)
-0.023
Liver disease; n (%)
3 (0.1%)
2 (0.1%)
0.0000
1 (0.0%)
1 (0.0%)
#DIV/0!
004 (0.1%)
003 (0.0%)
0.045
Osteoarthritis; n (%)
337 (13.5%)
342 (13.7%)
-0.0058
423 (8.8%)
424 (8.8%)
0.0000
760 (10.4%)
766 (10.5%)
-0.003
Other arthritis, arthropathies and musculoskeletal pain; n ( 768 (30.7%)
773 (30.9%)
-0.0043
1,282 (26.7%)
1,303 (27.1%)
-0.0090
2,050 (28.1%)
2,076 (28.4%)
-0.007
Dorsopathies; n (%)
534 (21.4%)
556 (22.3%)
-0.0218
872 (18.2%)
879 (18.3%)
-0.0026
1,406 (19.3%)
1,435 (19.7%)
-0.010
Fractures; n (%)
44 (1.8%)
52 (2.1%)
-0.0217
67 (1.4%)
67 (1.4%)
0.0000
111 (1.5%)
119 (1.6%)
-0.008
Falls v2; n (%)
29 (1.2%)
32 (1.3%)
-0.0090
28 (0.6%)
26 (0.5%)
0.0135
057 (0.8%)
058 (0.8%)
0.000
Osteoporosis; n (%)
63 (2.5%)
56 (2.2%)
0.0198
49 (1.0%)
40 (0.8%)
0.0212
112 (1.5%)
096 (1.3%)
0.017
Depression; n (%)
259 (10.4%)
241 (9.6%)
0.0267
320 (6.7%)
321 (6.7%)
0.0000
579 (7.9%)
562 (7.7%)
0.007
Anxiety; n (%)
323 (12.9%)
318 (12.7%)
0.0060
386 (8.0%)
391 (8.1%)
-0.0037
709 (9.7%)
709 (9.7%)
0.000
Sleep_Disorder; n (%)
153 (6.1%)
148 (5.9%)
0.0084
335 (7.0%)
333 (6.9%)
0.0039
488 (6.7%)
481 (6.6%)
0.004
Dementia; n (%)
34 (1.4%)
25 (1.0%)
0.0367
20 (0.4%)
24 (0.5%)
-0.0149
054 (0.7%)
049 (0.7%)
0.000
Delirium; n (%)
19 (0.8%)
19 (0.8%)
0.0000
19 (0.4%)
19 (0.4%)
0.0000
038 (0.5%)
038 (0.5%)
0.000
Psychosis; n (%)
11 (0.4%)
13 (0.5%)
-0.0149
17 (0.4%)
13 (0.3%)
0.0169
028 (0.4%)
026 (0.4%)
0.000
Use of medications
Use of ACE inhibitors; n (%)
1,332 (53.3%)
1,316 (52.7%)
0.0120
2,689 (56.0%)
2,716 (56.6%)
-0.0121
4,021 (55.1%)
4,032 (55.2%)
-0.002
Use of ARBs; n (%)
486 (19.5%)
498 (19.9%)
-0.0101
879 (18.3%)
855 (17.8%)
0.0130
1,365 (18.7%)
1,353 (18.5%)
0.005
Use of Loop Diuretics - United; n (%)
193 (7.7%)
190 (7.6%)
0.0038
254 (5.3%)
286 (6.0%)
-0.0303
447 (6.1%)
476 (6.5%)
-0.016
Use of other diuretics- United; n (%)
98 (3.9%)
103 (4.1%)
-0.0102
188 (3.9%)
207 (4.3%)
-0.0202
286 (3.9%)
310 (4.2%)
-0.015
Use of nitrates-United; n (%)
1,089 (43.6%)
1,086 (43.5%)
0.0020
2,102 (43.8%)
2,128 (44.3%)
-0.0101
3,191 (43.7%)
3,214 (44.0%)
-0.006
Use of other hypertension drugs; n (%)
93 (3.7%)
94 (3.8%)
-0.0053
150 (3.1%)
163 (3.4%)
-0.0169
243 (3.3%)
257 (3.5%)
-0.011
Use of digoxin- United; n (%)
21 (0.8%)
20 (0.8%)
0.0000
18 (0.4%)
21 (0.4%)
0.0000
039 (0.5%)
041 (0.6%)
-0.014
Use of Anti-arrhythmics; n (%)
40 (1.6%)
42 (1.7%)
-0.0079
73 (1.5%)
74 (1.5%)
0.0000
113 (1.5%)
116 (1.6%)
-0.008
Use of COPD/asthma meds- United; n (%)
336 (13.5%)
315 (12.6%)
0.0267
529 (11.0%)
526 (11.0%)
0.0000
865 (11.8%)
841 (11.5%)
0.009
Use of statins; n (%)
2,267 (90.8%)
2,280 (91.3%)
-0.0175
4,415 (91.9%)
4,394 (91.5%)
0.0145
6,682 (91.5%)
6,674 (91.4%)
0.004
Use of other lipid-lowering drugs; n (%)
179 (7.2%)
189 (7.6%)
-0.0153
387 (8.1%)
408 (8.5%)
-0.0145
566 (7.8%)
597 (8.2%)
-0.015
Use of antiplatelet agents; n (%)
197 (7.9%)
217 (8.7%)
-0.0290
322 (6.7%)
359 (7.5%)
-0.0312
519 (7.1%)
576 (7.9%)
-0.030
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixa56 (2.2%)
58 (2.3%)
-0.0067
106 (2.2%)
113 (2.4%)
-0.0133
162 (2.2%)
171 (2.3%)
-0.007
Use of heparin and other low-molecular weight heparins; n6 (0.2%)
8 (0.3%)
-0.0200
0 (0.0%)
0 (0.0%)
#DIV/0!
006 (0.1%)
008 (0.1%)
0.000
Use of NSAIDs; n (%)
315 (12.6%)
339 (13.6%)
-0.0296
700 (14.6%)
702 (14.6%)
0.0000
1,015 (13.9%)
1,041 (14.3%)
-0.011
Use of oral corticosteroids; n (%)
386 (15.5%)
372 (14.9%)
0.0167
660 (13.7%)
671 (14.0%)
-0.0087
1,046 (14.3%)
1,043 (14.3%)
0.000
Use of bisphosphonate (United); n (%)
25 (1.0%)
22 (0.9%)
0.0103
20 (0.4%)
16 (0.3%)
0.0169
045 (0.6%)
038 (0.5%)
0.014
Use of opioids- United; n (%)
540 (21.6%)
533 (21.3%)
0.0073
998 (20.8%)
989 (20.6%)
0.0049
1,538 (21.1%)
1,522 (20.8%)
0.007
Use of antidepressants; n (%)
421 (16.9%)
409 (16.4%)
0.0134
746 (15.5%)
735 (15.3%)
0.0055
1,167 (16.0%)
1,144 (15.7%)
0.008
Use of antipsychotics; n (%)
22 (0.9%)
27 (1.1%)
-0.0201
36 (0.7%)
45 (0.9%)
-0.0225
058 (0.8%)
072 (1.0%)
-0.021
Use of anticonvulsants; n (%)
198 (7.9%)
199 (8.0%)
-0.0037
286 (6.0%)
296 (6.2%)
-0.0084
484 (6.6%)
495 (6.8%)
-0.008
Use of Benzos- United; n (%)
249 (10.0%)
247 (9.9%)
0.0033
457 (9.5%)
466 (9.7%)
-0.0068
706 (9.7%)
713 (9.8%)
-0.003
Use of anxiolytics/hypnotics- United; n (%)
128 (5.1%)
123 (4.9%)
0.0092
242 (5.0%)
240 (5.0%)
0.0000
370 (5.1%)
363 (5.0%)
0.005
Use of dementia meds- United; n (%)
15 (0.6%)
13 (0.5%)
0.0135
5 (0.1%)
7 (0.1%)
0.0000
020 (0.3%)
020 (0.3%)
0.000
Use of antiparkinsonian meds- United; n (%)
27 (1.1%)
31 (1.2%)
-0.0094
46 (1.0%)
38 (0.8%)
0.0212
073 (1.0%)
069 (0.9%)
0.010
Appendix B

Use of glucose test strips; n (%)
29 (1.2%)
31 (1.2%)
0.0000
58 (1.2%)
60 (1.2%)
0.0000
087 (1.2%)
091 (1.2%)
0.000
Use of thiazide- United; n (%)
192 (7.7%)
188 (7.5%)
0.0075
329 (6.9%)
317 (6.6%)
0.0120
521 (7.1%)
505 (6.9%)
0.008
Use of beta blockers; n (%)
2,164 (86.6%)
2,160 (86.5%)
0.0029
4,241 (88.3%)
4,252 (88.5%)
-0.0062
6,405 (87.7%)
6,412 (87.8%)
-0.003
Use of calcium channel blockers; n (%)
462 (18.5%)
460 (18.4%)
0.0026
780 (16.2%)
803 (16.7%)
-0.0135
1,242 (17.0%)
1,263 (17.3%)
-0.008
Use of aspirin; n (%)
312 (12.5%)
320 (12.8%)
-0.0090
798 (16.6%)
782 (16.3%)
0.0081
1,110 (15.2%)
1,102 (15.1%)
0.003
Use of Low Intensity Statins; n (%)
626 (25.1%)
633 (25.3%)
-0.0046
1,268 (26.4%)
1,257 (26.2%)
0.0045
1,894 (25.9%)
1,890 (25.9%)
0.000
Use of High Intensity Statins; n (%)
1,910 (76.5%)
1,892 (75.7%)
0.0188
3,661 (76.2%)
3,566 (74.3%)
0.0440
5,571 (76.3%)
5,458 (74.8%)
0.035
Use of Sympatomimetic agents; n (%)
27 (1.1%)
31 (1.2%)
-0.0094
46 (1.0%)
49 (1.0%)
0.0000
073 (1.0%)
080 (1.1%)
-0.010
Use of CNS stimulants; n (%)
5 (0.2%)
6 (0.2%)
0.0000
27 (0.6%)
27 (0.6%)
0.0000
032 (0.4%)
033 (0.5%)
-0.015
All antidiabetic medications except Insulin; n (%)
560 (22.4%)
587 (23.5%)
-0.0262
1,099 (22.9%)
1,109 (23.1%)
-0.0048
1,659 (22.7%)
1,696 (23.2%)
-0.012
DM Medications - Insulin Copy; n (%)
217 (8.7%)
219 (8.8%)
-0.0035
444 (9.2%)
454 (9.5%)
-0.0103
661 (9.1%)
673 (9.2%)
-0.003
Use of estrogens, progestins, androgens; n (%)
87 (3.5%)
93 (3.7%)
-0.0107
210 (4.4%)
216 (4.5%)
-0.0048
297 (4.1%)
309 (4.2%)
-0.005
Use of Angiogenesis inhibitors; n (%)
1 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
001 (0.0%)
000 (0.0%)
#DIV/0!
Use of Oral Immunosuppressants; n (%)
3 (0.1%)
3 (0.1%)
0.0000
10 (0.2%)
9 (0.2%)
0.0000
013 (0.2%)
012 (0.2%)
0.000
Use of fondaparinux or Bivalirudin; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
1 (0.0%)
#DIV/0!
000 (0.0%)
001 (0.0%)
#DIV/0!
Use of other direct thrombin inhibitors (lepirudin, desirudin0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
000 (0.0%)
000 (0.0%)
#DIV/0!
Use of CYP inhibitors; n (%)
406 (16.3%)
407 (16.3%)
0.0000
723 (15.1%)
743 (15.5%)
-0.0111
1,129 (15.5%)
1,150 (15.8%)
-0.008
Use of CYP inducers; n (%)
6 (0.2%)
8 (0.3%)
-0.0200
19 (0.4%)
16 (0.3%)
0.0169
025 (0.3%)
024 (0.3%)
0.000
Burden of disease/Healthcare utilization
Combined comorbidity score, 180 days Copy
...mean (sd)
1.19 (1.81)
1.21 (1.83)
-0.0110
0.60 (1.47)
0.61 (1.47)
-0.0068
0.80 (1.59)
0.82 (1.60)
-0.013
...median [IQR]
1.00 [0.00, 2.00]
1.00 [0.00, 2.00]
0.0000
0.00 [-1.00, 1.00]
0.00 [-1.00, 1.00]
0.0000
0.34 (1.59)
0.34 (1.60)
0.000
Frailty Score (mean): Empirical Version 365 days, v2
...mean (sd)
0.18 (0.04)
0.18 (0.04)
0.0000
0.17 (0.03)
0.17 (0.03)
0.0000
0.17 (0.03)
0.17 (0.03)
0.000
...median [IQR]
0.17 [0.15, 0.20]
0.17 [0.15, 0.20]
0.0000
0.16 [0.14, 0.18]
0.16 [0.15, 0.18]
0.0000
0.16 (0.03)
0.16 (0.03)
0.000
Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level 
...mean (sd)
8.40 (8.59)
8.76 (8.97)
-0.0410
6.01 (7.71)
6.05 (7.67)
-0.0052
6.83 (8.02)
6.98 (8.14)
-0.019
...median [IQR]
7.00 [0.00, 14.00]
8.00 [0.00, 14.00]
-0.1139
0.00 [0.00, 12.00]
0.00 [0.00, 12.00]
0.0000
2.40 (8.02)
2.74 (8.14)
-0.042
HAS-BLED Score (ICD-9 and ICD-10), 180 days
...mean (sd)
3.43 (0.57)
3.43 (0.58)
0.0000
3.16 (0.46)
3.15 (0.45)
0.0220
3.25 (0.50)
3.25 (0.50)
0.000
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.0000
3.00 [3.00, 3.00]
3.00 [3.00, 3.00]
0.0000
3.00 (0.50)
3.00 (0.50)
0.000
number of different/distinct medication prescriptions
...mean (sd)
8.75 (4.38)
8.77 (4.50)
-0.0045
8.58 (4.15)
8.63 (4.23)
-0.0119
8.64 (4.23)
8.68 (4.32)
-0.009
...median [IQR]
8.00 [6.00, 11.00]
8.00 [5.00, 11.00]
0.0000
8.00 [6.00, 11.00]
8.00 [6.00, 11.00]
0.0000
8.00 (4.23)
8.00 (4.32)
0.000
Any hospitalization within prior 30 days; n (%)
2,498 (100.0%)
2,498 (100.0%)
#DIV/0!
4,802 (100.0%)
4,802 (100.0%)
#DIV/0!
7,300 (100.0%)
7,300 (100.0%)
#DIV/0!
Number of Hospitalizations
...mean (sd)
1.08 (0.30)
1.08 (0.32)
0.0000
1.06 (0.28)
1.06 (0.26)
0.0000
1.07 (0.29)
1.07 (0.28)
0.000
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.0000
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.0000
1.00 (0.29)
1.00 (0.28)
0.000
Number of hospital days
...mean (sd)
3.61 (1.95)
3.60 (2.15)
0.0049
3.48 (2.00)
3.50 (1.64)
-0.0109
3.52 (1.98)
3.53 (1.83)
-0.005
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.0000
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.0000
3.00 (1.98)
3.00 (1.83)
0.000
Number of Emergency Department (ED) visits v3
...mean (sd)
1.09 (1.26)
1.10 (1.37)
-0.0076
3.59 (5.64)
3.62 (6.71)
-0.0048
2.73 (4.63)
2.76 (5.50)
-0.006
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.0000
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.0000
1.66 (4.63)
1.66 (5.50)
0.000
Number of Office visits
...mean (sd)
2.98 (3.14)
3.03 (3.30)
-0.0155
2.69 (2.85)
2.70 (2.91)
-0.0035
2.79 (2.95)
2.81 (3.05)
-0.007
...median [IQR]
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 (2.95)
2.00 (3.05)
0.000
Number of internal medicine/family medicine visits
...mean (sd)
6.26 (8.89)
6.47 (10.55)
-0.0215
3.83 (5.90)
3.86 (6.58)
-0.0048
4.66 (7.07)
4.75 (8.16)
-0.012
...median [IQR]
3.00 [1.00, 8.00]
3.00 [1.00, 8.00]
0.0000
2.00 [0.00, 5.00]
2.00 [0.00, 5.00]
0.0000
2.34 (7.07)
2.34 (8.16)
0.000
Number of Cardiologist visits
Appendix B

...mean (sd)
8.18 (5.00)
8.14 (5.05)
0.0080
1.00 (2.09)
1.02 (2.27)
-0.0092
3.46 (3.38)
3.46 (3.48)
0.000
...median [IQR]
8.00 [5.00, 11.00]
7.00 [5.00, 10.00]
0.1990
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.0000
2.74 (3.38)
2.40 (3.48)
0.099
Number electrocardiograms received v2
...mean (sd)
3.33 (2.45)
3.33 (2.62)
0.0000
0.97 (1.32)
0.97 (1.36)
0.0000
1.78 (1.79)
1.78 (1.89)
0.000
...median [IQR]
3.00 [2.00, 4.00]
3.00 [2.00, 5.00]
0.0000
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.0000
1.68 (1.79)
1.68 (1.89)
0.000
Number of BNP tests
...mean (sd)
0.11 (0.37)
0.10 (0.40)
0.0260
0.12 (0.37)
0.12 (0.38)
0.0000
0.12 (0.37)
0.11 (0.39)
0.026
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.37)
0.00 (0.39)
0.000
Number of Cardiac biomarkers tests (tropnin, CK-MBs, Myo
...mean (sd)
0.68 (1.63)
0.73 (1.73)
-0.0297
0.72 (1.67)
0.73 (1.60)
-0.0061
0.71 (1.66)
0.73 (1.65)
-0.012
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 1.00]
0.0000
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.0000
0.00 (1.66)
0.00 (1.65)
0.000
Number of Ambulatory Blood pressure monitoring tests
...mean (sd)
0.00 (0.03)
0.00 (0.02)
0.0000
0.00 (0.04)
0.00 (0.03)
0.0000
0.00 (0.04)
0.00 (0.03)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.04)
0.00 (0.03)
0.000
N of days on antihypertensive medications during baseline
...mean (sd)
75.35 (78.69)
75.92 (78.36)
-0.0073
71.06 (77.53)
71.15 (77.62)
-0.0012
72.53 (77.93)
72.78 (77.87)
-0.003
...median [IQR]
31.00 [1.00, 168.00] 35.00 [1.00, 168.00]
-0.0509
14.00 [1.00, 163.00] 12.00 [1.00, 164.00]
0.0258
19.82 (77.93)
19.87 (77.87)
-0.001
N of days in database anytime prior
...mean (sd)
1,658.31 (1,306.21) 1,660.85 (1,331.74)
-0.0019
1,989.48 (1,379.50) 1,998.92 (1,372.00)
-0.0069
1876.16 (1354.87)
1883.24 (1358.36)
-0.005
...median [IQR]
1,246.00 [612.00, 2,41,227.50 [593.75, 2,4
0.0140
1,682.50 [800.00, 3,01,693.00 [824.75, 3,0
-0.0076
1533.13 (1354.87)
1533.71 (1358.36)
0.000
Mean Copay for per prescription cost (charges in U.S. $) (18
...mean (sd)
23.00 (28.64)
23.95 (28.18)
-0.0334
16.82 (22.87)
16.49 (20.73)
0.0151
18.93 (24.99)
19.04 (23.55)
-0.005
...median [IQR]
14.98 [6.00, 29.47]
15.31 [6.44, 30.82]
-0.0116
10.69 [2.63, 22.50]
10.42 [2.98, 22.00]
0.0124
12.16 (24.99)
12.09 (23.55)
0.003
...Missing; n (%)
351 (14.1%)
361 (14.5%)
-0.0114
739 (15.4%)
743 (15.5%)
-0.0028
1,090 (14.9%)
1,104 (15.1%)
-0.006
Duration of index hospitalization (i.e. anchor hospitalizatio
...mean (sd)
1.00 (0.00)
1.00 (0.00)
#DIV/0!
1.00 (0.00)
1.00 (0.00)
#DIV/0!
1.00 (0.00)
1.00 (0.00)
#DIV/0!
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
#DIV/0!
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
#DIV/0!
1.00 (0.00)
1.00 (0.00)
#DIV/0!
N of Generic name drugs
...mean (sd)
12.43 (11.07)
12.50 (11.04)
-0.0063
10.82 (9.17)
10.89 (9.29)
-0.0076
11.37 (9.86)
11.44 (9.92)
-0.007
...median [IQR]
9.00 [5.00, 16.00]
9.00 [5.00, 16.00]
0.0000
8.00 [4.00, 14.00]
8.00 [4.00, 14.00]
0.0000
8.34 (9.86)
8.34 (9.92)
0.000
N of Brand name drugs
...mean (sd)
3.15 (3.47)
3.17 (4.09)
-0.0053
3.53 (3.65)
3.59 (3.74)
-0.0162
3.40 (3.59)
3.45 (3.86)
-0.013
...median [IQR]
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.0000
2.00 (3.59)
2.00 (3.86)
0.000
Number of D-dimer tests
...mean (sd)
0.06 (0.26)
0.06 (0.26)
0.0000
0.07 (0.30)
0.07 (0.28)
0.0000
0.07 (0.29)
0.07 (0.27)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.29)
0.00 (0.27)
0.000
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.05 (0.27)
0.04 (0.24)
0.0391
0.04 (0.25)
0.04 (0.24)
0.0000
0.04 (0.26)
0.04 (0.24)
0.000
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (0.26)
0.00 (0.24)
0.000
Number of PT or aPTTt tests
...mean (sd)
0.37 (1.05)
0.37 (1.00)
0.0000
0.39 (0.98)
0.40 (1.02)
-0.0100
0.38 (1.00)
0.39 (1.01)
-0.010
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.0000
0.00 (1.00)
0.00 (1.01)
0.000
Number of Bleeding time tests
...mean (sd)
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.00)
0.00 (0.00)
#DIV/0!
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
#DIV/0!
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
#DIV/0!
0.00 (0.00)
0.00 (0.00)
#DIV/0!
Occurrence of creatinine tests  ordered (for PS); n (%)
68 (2.7%)
68 (2.7%)
0.0000
119 (2.5%)
130 (2.7%)
-0.0126
187 (2.6%)
198 (2.7%)
-0.006
Cardiovascular stress test; n (%)
8 (0.3%)
5 (0.2%)
0.0200
10 (0.2%)
10 (0.2%)
0.0000
018 (0.2%)
015 (0.2%)
0.000
Echocardiogram; n (%)
1,774 (71.0%)
1,764 (70.6%)
0.0088
3,228 (67.2%)
3,232 (67.3%)
-0.0021
5,002 (68.5%)
4,996 (68.4%)
0.002
Colonoscopy; n (%)
79 (3.2%)
84 (3.4%)
-0.0112
178 (3.7%)
177 (3.7%)
0.0000
257 (3.5%)
261 (3.6%)
-0.005
Fecal occult blood (FOB) test; n (%)
67 (2.7%)
69 (2.8%)
-0.0061
114 (2.4%)
116 (2.4%)
0.0000
181 (2.5%)
185 (2.5%)
0.000
Flu vaccine; n (%)
348 (13.9%)
337 (13.5%)
0.0116
412 (8.6%)
404 (8.4%)
0.0072
760 (10.4%)
741 (10.2%)
0.007
Appendix B

Mammogram; n (%)
116 (4.6%)
120 (4.8%)
-0.0095
156 (3.2%)
168 (3.5%)
-0.0167
272 (3.7%)
288 (3.9%)
-0.010
Pap smear; n (%)
49 (2.0%)
49 (2.0%)
0.0000
100 (2.1%)
96 (2.0%)
0.0071
149 (2.0%)
145 (2.0%)
0.000
Pneumonia vaccine; n (%)
377 (15.1%)
400 (16.0%)
-0.0248
343 (7.1%)
331 (6.9%)
0.0078
720 (9.9%)
731 (10.0%)
-0.003
PSA test or Prostate exam for DRE; n (%)
380 (15.2%)
385 (15.4%)
-0.0056
621 (12.9%)
632 (13.2%)
-0.0089
1,001 (13.7%)
1,017 (13.9%)
-0.006
Bone mineral density; n (%)
39 (1.6%)
41 (1.6%)
0.0000
34 (0.7%)
32 (0.7%)
0.0000
073 (1.0%)
073 (1.0%)
0.000
Drug eluting stent; n (%)
826 (33.1%)
800 (32.0%)
0.0235
1,804 (37.6%)
1,804 (37.6%)
0.0000
2,630 (36.0%)
2,604 (35.7%)
0.006
Bare metal stent; n (%)
2,143 (85.8%)
2,146 (85.9%)
-0.0029
3,978 (82.8%)
3,958 (82.4%)
0.0106
6,121 (83.8%)
6,104 (83.6%)
0.005
Appendix B